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Summary 
 
Malaria is one of the leading causes of illness and death in Papua New Guinea (PNG), mainly 
affecting children under 5 years of age. The current first line treatment for uncomplicated 
malaria is a combination therapy of sulfadoxine-pyrimethamine and chloroquine (CQ) or 
amodiaquine, however, frequent treatment failures have been reported shortly after its 
implementation. Drug resistance has mainly been associated with single nucleotide 
polymorphisms in five different genes. Different studies have indicated that mutations 
associated with drug resistance incur fitness costs to the parasite in absence of drug pressure. 
Among these are reports from different countries where a decreasing prevalence of mutations 
associated with CQ resistance was observed after CQ has been suspended as first line 
treatment. As it is experimentally difficult to estimate the fitness of Plasmodium parasites, a 
surrogate marker is needed to quantify fitness costs associated with drug resistance mutations. 
We hypothesised that the parasites’ survival within the human host can be used as surrogate 
marker for parasite fitness. In a pilot study we determined the drug resistance-associated 
haplotypes of parasite clones at 25 loci on 4 marker genes, and compared their prevalence 
between newly acquired and chronic infections. A reduced frequency of a 7-fold mutated 
haplotype and increased frequency of a 5-fold mutated haplotype in long term persistent 
infections indicated an impaired survival of highly mutated parasites and suggested that the 
duration of infections is a promising marker for parasite fitness that deserved further 
investigation. 
 
A further approach to define duration of infections more precisely was undertaken with 
samples from a longitudinal field survey in PNG. A cohort of 269 1-4.5 years old children 
was followed over a period of 16 months. This provided consecutive blood samples collected 
in 2-monthly follow-up visits plus a blood sample from each morbid episode. All samples 
were genotyped for the polymorphic marker gene merozoite surface protein 2 (msp2) in order 
to distinguish individual parasite clones within a host. The persistence of genotypes in 
consecutive blood samples of each child was determined. Unexpected high numbers of 
antimalarial treatments given in the course of this study led to a high turn-over rate of parasite 
clones and prevented the establishment of asymptomatic long-term infections. The shortage of 
long untreated periods in our study participants hampered the determination of a novel 
molecular parameter termed “duration of infection” for each individual parasite clone. This 
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parameter could have been useful for modelling the transmission success and fitness of drug 
resistant versus drug sensitive parasite clones. We concluded that this approach requires a 
cohort of semi-immune individuals where treatment is given rarely, e.g. older children or 
adults, where P. falciparum infections less frequently cause morbid episodes. 
 
The high incidence of morbidity in our study cohort allowed us to investigate molecular 
parameters that have an impact on the development of a subsequent clinical episode. We 
found that in children >3 years, a higher multiplicity of infection (MOI) at baseline reduced 
the risk of a P. falciparum episode. These results are in agreement with previous reports and 
support the concept of premunition. Furthermore, we studied the impact of co-infecting 
Plasmodium species on MOI and found an increased MOI in the presence of a heterologous 
species. This can be explained by the observation of reduced parasite densities in mixed-
species infections, leading to a decreased need for treatment and thus facilitating the 
accumulation of multiple clones. Our results provide further evidence for interactions among 
co-infecting P. falciparum clones as well as among co-infecting Plasmodium species.  
 
During the 16 months field survey all morbid episodes were treated with Coartem®. Analysis 
of msp2 genotyping results revealed an unexpected high number of Coartem® treatment 
failures. After confirmation of recrudescent parasites with 2 additional marker genes and 
exclusion of host genetic factors to be responsible for treatment failures, the most likely 
explanation for the frequently observed Coartem® failures was a combination of poor 
adherence to the treatment regimen and a lack of fat supplementation which is required for 
absorption of the drug. Our results disagree with findings from a clinical trial reporting 
Coartem® to be highly effective in PNG. In contrast, our observations from a non-trial setting 
highlight potential problems of Coartem® usage in routine clinical practice. 
 
In the course of this thesis, genotyping techniques for merozoite surface proteins (msp) 1 and 
2 were optimized and applied. Using these high resolution typing techniques based on 
capillary electrophoresis, we investigated the effect of transmission intensity on diversity and 
complexity of msp1 and msp2 in samples from PNG and Tanzania. We observed a greater 
MOI and a greater number of distinct alleles in samples from Tanzania. Genetic diversity was 
greater for msp2 than for msp1. In both these areas of different malaria endemicity msp2 was 
found to be superior for distinguishing individual parasite clones. The probability of two 
infections carrying by chance the same msp2 allele was lower than this probability calculated 
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for msp1. Based on the frequency distribution of msp2 alleles and on the distribution of 
observed numbers of infections, we estimated the true MOI adjusted for the probability of 
multiple infections sharing the same allele. For our high resolution typing technique this 
adjustment made little difference to the estimated mean MOI compared to the observed mean 
MOI. 
 
A central aim of this thesis was to measure molecular parameters of infection dynamics. 
These can be determined from genotyping longitudinal sets of samples. Some of these 
parameters were successfully determined: MOI, force of infection (FOI), and detectability. 
Other parameters such as natural elimination rates and persistence of infections could not be 
determined due to frequent treatments. We estimated detectability of parasite clones based on 
samples collected 24 hours apart and investigated its impact on the MOI and FOI. Imperfect 
detection of parasites occurs as a consequence of sequestration or when parasite densities 
fluctuate around the detection limit. We found that in our study participants detectability was 
high. This was likely an effect of high parasite densities in children of this age. The benefit of 
short-term sampling on measures of MOI and FOI was marginal. We concluded that in future 
studies carried out in this age group, taking repeated samples 24 hours apart has limited 
benefit and does not justify the additional costs, work load and discomfort for the study 
participants.  
 
This project contributed to our understanding of the infections dynamics of P. falciparum and 
the interactions between parasites clones and Plasmodium species. We provided further 
insights into determinants of malaria episodes and highlighted the potential usefulness of the 
parameter “duration of infection” as surrogate marker to estimate fitness costs of drug 
resistance. This thesis provided findings that are relevant for malaria control strategies and 
treatment guidelines 
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Zusammenfassung 
 
Malaria ist eine der hauptsächlichen Krankheits- und Todesursachen in Papua Neuguinea 
(PNG) und betrifft vor allem Kinder unter fünf Jahren. Die Standardbehandlung für 
unkomplizierte Malaria ist derzeit eine Kombination aus Sulfadoxin-Pyrimethamin plus 
entweder Chloroquin (CQ) oder Amodiaquin. Schon kurz nach der Einführung dieser 
Therapie beobachtete man hohe Misserfolgsraten. Medikamentenresistenz ist vor allem auf 
Punktmutationen in fünf verschiedenen Genen zurückzuführen. Verschiedene Studien haben 
gezeigt, dass Mutationen, die mit Medikamentenresistenz in Zusammenhang stehen, die 
Fitness von Parasiten beeinträchtigen. Dies gilt jedoch nur in Abwesenheit von 
Malariamedikamenten. Einige Länder verzeichneten einen Rückgang der Marker für CQ-
Resistenz, nachdem CQ als Standardbehandlung für Malaria abgesetzt wurde. Die Fitness von 
Plasmodien kann experimentell nur sehr aufwändig bestimmt werden. Daher ist es von 
Vorteil, einen Marker zu finden, der eine Quantifikation der Fitness-Kosten, die durch 
Punktmutationen verursacht werden, erlaubt. Unserer Arbeitshypothese lag die Annahme 
zugrunde, dass sich die Überlebensdauer der Parasiten im Wirt als ein solcher Marker für 
Parasiten-Fitness eignen könnte. Daher haben wir für einzelne Parasitenklone ein genetisches 
Resistenzprofil erststellt, das sich aus 25 Punktmutationen in vier verschiedenen Markergenen 
zusammensetzt. Diese so genannten „Haplotypen“ wurden zwischen Neuinfektionen und 
chronischen Infektionen verglichen. Die Anzahl von Parasiten mit sieben Mutationen nahm 
ab, dagegen stieg die Anzahl fünf-fach mutierter Parasiten in Langzeit-Infektionen an. Dies 
führte zu dem Schluss, dass die Überlebensdauer von Parasiten mit einer hohen Anzahl an 
Punktmutationen beeinträchtigt ist. Diese Ergebnisse deuteten darauf hin, dass die Dauer 
einer Parasiteninfektion im Wirt ein geeignetes Mass für Parasiten-Fitness ist.  
 
In einem weiteren Schritt wurden die Proben einer Langzeitstudie aus PNG verwendet, um 
die Infektionsdauer präziser zu bestimmen. 250 Kinder zwischen einem und viereinhalb 
Jahren wurden über einen Zeitraum von 16 Monaten beobachtet. Während dieser Zeit wurden 
Blutproben in Abständen von 2 Monaten gesammelt. Weitere Proben wurden beim Auftreten 
von Malariasymptomen bei den Studienteilnehmern gesammelt. Um einzelne, in einem Wirt 
gleichzeitig vorhandene Parasitenklone zu unterscheiden, wurde bei allen Blutproben, die P. 
falciparum enthielten, das polymorphe Parasitengen „Merozoitenoberflächenprotein 2“ 
(msp2) genotypisiert. Die Überlebensdauer aller Genotypen wurde anhand von 
aufeinanderfolgenden Blutproben aus der Langzeitstudie bestimmt. Eine unerwartet hohe 
ZUSAMMENFASSUNG 
 12 
Anzahl von Behandlungen führte jedoch zu starker Fluktuation der Parasitenklone, so dass 
sich fast keine asymptomatischen Langzeitinfektionen etablieren konnten. Die 
Infektionsdauer wäre sowohl für die Schätzung der Übertragungsrate als auch zum Vergleich 
der Fitness zwischen medikamentenresistenten und nicht-resistenten Parasiten nützlich. 
Unsere bei kleinen Kindern gewonnenen Ergebnisse zeigten jedoch, dass für diesen 
Versuchsansatz semi-immune Studienteilnehmer, wie z.B. ältere Kinder oder Erwachsene, 
besser geeignet wären, da in diesen Altersgruppen neue P. falciparum Infektionen weniger 
häufig zu klinischen Episoden führen.  
 
Die hohe Inzidenz an Krankheitsfällen in Teilnehmern unserer Studie ermöglichte eine 
genaue Ermittlung parasitologischer Faktoren, die den Verlauf einer Infektion beeinflussen. 
Eine hohe Anzahl Infektionen hat bei Kindern über drei Jahren das Risiko einer 
nachfolgenden klinischen Episode signifikant reduziert. Diese Resultate bestätigen frühere 
Berichte und stützen die Hypothese, dass bereits bestehende Infektionen vor Neuinfektion 
schützen („premunition“). Weiterhin untersuchten wir den Einfluss einer Co-Infektion mit 
weiteren Plasmodium Arten auf die Anzahl von P. falciparum Klonen pro Wirt und konnten 
zeigen, dass diese in Anwesenheit weiterer Plasmodium Arten erhöht war. Eine mögliche 
Erklärung hierfür könnte die geringere Parasitendichte in Spezies-Mischinfektionen sein, die 
den Behandlungsbedarf reduzierte und somit eine Akkumulierung verschiedener Klone 
erlaubte. Unsere Ergebnisse liefern weitere Hinweis auf eine gegenseitige Beeinflussung 
mehrerer Parasitenklone als auch mehrerer Plasmodium Arten, sofern sie den gleichen Wirt 
besiedeln.  
 
Während der 16-monatigen Studie wurden alle klinischen Malariaepisoden mit Coartem® 
behandelt. Die Ergebnisse der msp2-Genotypisierung zeigten, dass diese Behandlung in 
vielen Fällen versagte. Behandlungsmisserfolge wurden durch Genotypisierung zweier 
weiterer Markergene bestätigt und genetische Wirtsfaktoren wurden als Grund für den 
Behandlungsmisserfolg ausgeschlossen. Die wahrscheinlichste Erklärung für häufiges 
Fehlschlagen der Coartem® Behandlung war, dass Behandlungsvorschriften nicht eingehalten 
wurden oder dass das Medikament nicht mit einer fettreichen Nahrung verabreicht wurde, 
welche zur Absorption der Wirkstoffe notwendig ist. Unsere Ergebnisse unterscheiden sich 
deutlich von den Resultaten einer klinischen Studie, die eine hohe Effizienz von Coartem® in 
PNG verzeichneten. Im Gegensatz zu diesen Berichten verdeutlichen unsere Ergebnisse 
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potentielle Probleme bei der alltäglichen Anwendung von Coartem® ausserhalb klinischer 
Studien.  
Im Verlauf dieser Doktorarbeit wurden die Methoden zur Genotypisierung von msp1 und 
msp2 optimiert und angewandt. Mit Hilfe hochauflösender Genotypisierungsmethoden, die 
auf Kapillarelektrophorese beruhen haben wir den Einfluss der Übertragungsintensität auf die 
Diversität und Komplexität von msp1 und msp2 in Proben von PNG und Tanzania (TZ) 
untersucht. Sowohl die Anzahl verschiedener Klone pro Wirt (Infektionsmultiplizität) als 
auch die Diversität waren in Proben aus TZ höher und msp2 wies eine höhere Diversität auf 
als msp1.In beiden Ländern, die sich stark in ihrer Malaria-Übertragungsrate unterscheiden, 
war msp2 das geeignetere Markergen um die einzelnen Parasitenklone zu unterscheiden, da 
die Wahrscheinlichkeit, dass zwei Parasiten durch Zufall das gleiche Allel tragen viel geringer 
war als für msp1. Anhand der Häufigkeitsverteilung der msp2-Allele und der Verteilung der 
Anzahl Klone pro Wirt haben wir die tatsächliche Multiplizität berechnet. Hierbei wurde die 
Möglichkeit, dass zwei Parasiten durch Zufall das gleiche Allel tragen berücksichtigt. Für die 
hier angewendete, hochauflösende Genotypisierungsmethode hat sich der berechnete Wert für 
die Multiplizität nur geringfügig von der gemessenen Anzahl unterschieden.  
 
Ein Hauptziel dieser Studie war es, die Infektionsdynamik mittels molekularer Parameter zu 
beschreiben. Diese Parameter können durch die Genotypisierung longitudinaler Datensätze 
ermittelt werden. In dieser Studie wurden einige dieser Parameter erfolgreich bestimmt: die 
Multiplizität, die Infektionsrate und die Nachweisbarkeit von P. falciparum Klonen. 
Parameter wie die natürliche Eliminierung von Parasiten durch den Wirt oder die 
Überlebensdauer der Parasiten Klone im Wirt konnten aufgrund häufiger Behandlungen mit 
Medikamenten nicht bestimmt werden. Anhand aller Proben, die im Abstand von 24 Stunden 
gesammelt wurden, wurde die Nachweisbarkeit der Klone geschätzt und die Auswirkung 
einer Datenerhebung in kurzen Zeitabständen auf die Multiplizität und auf die Infektionsrate 
untersucht. Ein unvollständiger Nachweis von Parasiten wird vor allem durch Sequestration 
verursacht, oder wenn Parasitendichten nahe bei der Nachweisgrenze des molekularen Tests 
liegen. Die Nachweisbarkeit von Parasitenklonen war in unseren Studienteilnehmern sehr 
hoch, was höchst wahrscheinlich auf hohe Parasitendichten in Kindern dieser Altersgruppe 
zurückzuführen ist. Datenerhebungen in Zeitintervallen von 24 Stunden hatten nur einen 
geringfügigen Einfluss auf die Anzahl detektierter Klone und die Infektionsrate. Der geringe 
Informationsgewinn, der durch die zweite Probe innerhalb von 24 Stunden erzielt wurde 
rechtfertigt weder die zusätzlichen Kosten, für die Durchführung und den zusätzlichen 
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Arbeitsaufwand noch die zusätzlichen Unannehmlichkeiten für die Studienteilnehmer. 
Deshalb raten wir für zukünftige Studien, die in dieser Altersgruppe durchgeführt werden 
davon ab zwei Proben innerhalb von 24 Stunden zu sammeln.  
Diese Arbeit hat  zum Verständnis sowohl der Infektionsdynamik als auch der Interaktion 
zwischen Parasitenklonen und Plasmodium Arten beigetragen. Weitere Erkenntnisse wurden 
über Faktoren gewonnen, die die Entwicklung einer klinischen Episode beeinflussen. Wir 
konnten aufzeigen, dass der Parameter „Infektionsdauer“ von Nutzen sein kann, um Fitness-
Kosten zu messen. In dieser Arbeit wurden Erkenntnisse gewonnen, die für Kontrollstrategien 
zur Bekämpfung von Malaria als auch für Richtlinien zur Behandlung von Malaria von 
Bedeutung sind.  
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Abbreviations 
 
ACT   Artemisinin-based combination therapy 
AQ  Amodiaquine 
CQ  Chloroquine 
DNA  Deoxyribonucleic acid  
FOI  force of infection 
FUB  follow-up bleed 
Hb  Haemoglobin level 
LDR-FMA Ligase detection reaction-fluorescent microsphere assay 
LR  likelihood ratio 
MOI  multiplicity of infection 
msp1  merozoite surface protein 1 
msp2  merozoite surface protein 2 
OR  odds ratio 
PCR  polymerase chain reaction 
pfcrt  Plasmodium falciparum chloroquine resistance transporter 
pfdhfr  Plasmodium falciparum dihydrofolate reductase  
pfdhps  Plasmodium falciparum dihydropteroate synthase 
pfmdr1  Plasmodium falciparum multidrug resistance gene 1 
PNG  Papua New Guinea 
RDT  rapid diagnostic test 
RFLP  restriction fragment length polymorphism 
SNP  single nucleotide polymorphism 
SP  Sulfadoxine-pyrimethamine 
STI  Swiss Tropical Institute 
TRS  treatment re-infection study 
TZ  Tanzania 
WHO  World Health Organization 
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CHAPTER 1: Introduction 
 
Malaria situation in Papua New Guinea 
Malaria is one of the leading causes of morbidity and mortality in Papua New Guinea (PNG) 
[1]. Its distribution within the country is very heterogeneous, ranging from highly endemic 
areas in the costal lowland [2-4] to absence of malaria with sporadic epidemic outbreaks in 
the highlands [5-7]. These regional differences observed within PNG are mainly attributable 
to the difference in temperature depending on altitude. In most lowland areas malaria 
transmission is perennial and shows limited seasonal variations [2-4], whereas endemicity 
decreases with increasing altitude [8-12]. In the areas of permanent transmission in PNG the 
main burden of malaria  is carried by young children, and both, the prevalence of infection as 
well as the incidence of morbidity peak in this age group [2,3,13-16]. No clear age 
relationship is observed in areas of low endemicity or of occasional epidemics, where most 
infections result in a clinical episodes even in adults [7].  
Severe malaria and malaria mortality are less frequent in PNG than in areas of comparable 
endemicity in Africa [17]. This could be related to the co-existence of all four Plasmodium 
species that affect humans which is a characteristic feature of the malaria situation in PNG. P. 
falciparum is the predominant species in most areas followed by P. vivax, and mixed species 
infections are common [2,3,8,15,18,19]. PNG therefore provides an optimal setting to study 
interactions between different Plasmodium species. So far, mechanisms of species 
interactions and the impact of mixed species on the epidemiology and morbidity of malaria 
are poorly understood and studies investigating  these topics have reported inconsistent results 
[19-21].  
 
The first line treatment against uncomplicated malaria in PNG has been chloroquine (CQ) or 
amodiaquine (AQ) monotherapy for a long time. A steadily declining efficacy of these drugs 
in PNG [22-25] has prompted health authorities to change the first line treatment to a 
combination therapy of CQ or AQ plus sulfadoxine-pyrimethamine (SP). However, a recent 
surveillance trial in three different provinces of PNG has reported treatment failure rates up to 
28% [26]. This highlights the rapid decrease in efficacy of this combination therapy only 
shortly after its implementation. In view of rapid failure of current first line drugs there is an 
urgent need for alternative treatment regimens. Artemisinin based combination therapies 
(ACT) are recommended by the World Health Organization (WHO) for countries where 
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conventional drugs are ineffective [27]. A recent drug trial in PNG has shown that the 
combination therapy of artemether and lumefantrine (Coartem®) was highly efficacious 
against P. falciparum infections [28] which gives a strong argument for the implementation of 
Coartem® as first line treatment in PNG.  
 
 
Genotyping and infection dynamics 
In the past two decades advances in the development of molecular genotyping techniques 
have made it possible to distinguish individual parasite clones within a host and numerous 
molecular epidemiological studies have increased our understanding of the parasite 
population structure in endemic countries. A hallmark of Plasmodium infections in highly 
endemic areas is the presence of concurrently infecting parasite clones within a host. The 
molecular markers most often used to discriminate P. falciparum clones are the genes of 
merozoite surface proteins 1 and 2 (msp1 and msp2) which are both highly polymorphic. 
Msp2 alleles can be grouped into 2 allelic families (3D7 and Fc27) according to a dimorphic 
non-repetitive region flanking a highly polymorphic domain of tandem repeats [29]. The size 
polymorphism of msp2 is generated by differences in copy number and length of the repeat 
units. The msp1 gene falls in three distinct allelic families (K1, MAD20 or RO33). Similar to 
msp2, the central repeat regions of MAD20-type and K1-type alleles give rise to size 
polymorphism and are flanked by family-specific sequences. The RO33 sequence does not 
contain any repeats [30]. Several genotyping techniques have been devised for studying 
genetic diversity in these two genes encoding surface antigens. All assays are based on PCR 
amplification of the central polymorphic region. Two commonly applied methods are: (i) 
sizing of PCR fragments on agarose gels. Identification of the allelic family is achieved by 
either use of family-specific primers [31] or by hybridization with family-specific probes 
[32], and (ii) restriction digestion of the amplified PCR products [33,34]. A more recent 
genotyping approach for msp2 is based on capillary electrophoresis of fluorescently labelled 
family-specific PCR fragments [35,36]. The major advantage of this technique lies in the 
accuracy of discriminating distinct parasite clones, even in complex mixtures, and in 
facilitating high throughput genotyping.  
 
Genotyping studies have shown that P. falciparum infected individuals from endemic areas 
generally harbour multi-clonal infections. Multiplicity of infection (MOI) describes the 
number of parasite genotypes simultaneously infecting one host. MOI does not only vary by 
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transmission intensity [37,38] but also by age. In endemic areas mean MOI generally 
increases up to the age of about 10 years and decreases thereafter during adolescence and 
adulthood [32,35,38,39].  
 
Genotyping samples collected in short term intervals revealed large fluctuations of parasite 
densities and genotype patters even from one day to another, suggesting that the detectable 
parasite clones are not stable over time, but rather exhibit highly complex daily dynamics 
[40,41]. These studies have emphasised that a single blood sample might not be representative 
for the complex parasite population present in an individual host. Important insights in the 
dynamics of Plasmodium infections can be gained by describing genotypes of parasite 
infections over time. Longitudinal studies have made it possible to track individual parasite 
clones over time and to determine acquisition and clearance rates. They also allow estimating 
the persistence of individual clones, and to study these parameters of infection dynamics with 
respect to age, seasonal variation or as an outcome measure of an intervention. Thus, 
molecular typing provides novel molecular malariological parameters. 
 
Acquired immunity affects the dynamics of clonal infections and it is therefore informative to 
conduct longitudinal genotyping surveys in different age groups. This will likely add to our 
understanding of developing immunity against malaria. In infants and young children in 
endemic areas, high MOI is a risk factor for clinical malaria [42,43], whereas in older children 
a high MOI was associated with protection against subsequent morbidity. The latter effect 
could be due to cross-protection against super-infecting parasites [13,44,45].  
 
Genotyping studies can greatly contribute to the understanding of interdependence between 
different Plasmodium species and between multiple clones of each species co-infecting one 
carrier. Previous studies reported that in areas sympatric for several Plasmodium species, 
mixed species infections are less common than expected by chance [46]. This implies some 
kind of interaction between species. How such effects may act upon a population of parasites 
composed of multiple competing clones has never been investigated in detail. Plasmodium 
species interactions within the human host were proposed to occur as a consequence of 
density dependent regulation. This was suggested by Bruce et al., (reviewed in [47]) from a 
study conducted in PNG, where the total parasite density within a host was found to fluctuate 
around a threshold, while densities of each species changed over time in a sequential pattern. 
It was proposed that density dependent regulation gets activated once the total parasite 
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population in a host reaches a certain density threshold, and that this regulation acts in a 
species transcending manner and therefore reduces total parasitaemia in a host.  
Few studies have reported a protective effect of co-infections with other species against 
severe malaria [48] or against a subsequent P. falciparum episode [21], whereas others failed 
to confirm these findings [19,20]. More prospective studies are needed to provide further 
evidence for Plasmodium species interactions in humans and ways these interactions operate.  
 
 
Fitness cost of drug resistance 
Advances in molecular typing have led to identification of a number of genetic events 
involved in or responsible for parasite resistance to antimalarial drugs. Among these are 
single nucleotide polymorphisms (SNP) or gene amplifications in genes encoding drug 
targets. Polymorphism in the P. falciparum chloroquine resistance transporter (pfcrt) is 
central to CQ resistance [49] with the mutation K76T playing a major role in determining the 
outcome of CQ treatment [50,51]. The role of P. falciparum multidrug resistance gene 1 
(pfmdr1) in drug resistance is controversial. Some authors found an association of certain 
SNPs, in particular the mutation N86Y, with chloroquine resistance (e.g. [51-53]) whereas 
others did not (e.g. [54,55]). Transfection experiments [56] showed that SNPs in the pfmdr1 
gene were involved in modulating the susceptibility to CQ and a joined action of the two 
genes pfcrt and pfmdr1 was suggested to be involved in high level CQ resistance [50]. No 
conclusive evidence was found so far for the importance of variations in copy number of the 
pfmdr1 gene on treatment outcome. Resistance to SP was found to be associated with 
polymorphism in the P. falciparum dihydrofolate reductase gene (Pfdhfr) (pyrimethamine 
resistance) [57-60] and the dihydropteroate synthase gene (Pfdhps) (sulfadoxine resistance) 
[61-63]. The mutation S108N in pfdhfr and A437G in pfdhps are considered the key 
mutations that confer resistance against SP, whereas the accumulation of additional mutations 
in these genes increases the level of resistance [59,61,64,65]. The calcium dependent 
ATPase6 is considered a target of Artemisinin drug action [66-68], however, field data on the 
involvement of ATPase6 mutations in drug resistance to Artemisinin are controversial.  
 
Mutations are thought to be costly for parasites in absence of drug pressure. Before the 
widespread use of antimalarial drugs, the frequency of resistant parasites was generally low, 
and only rose in response to drug pressure [69]. The frequency at which drug resistance 
alleles occur in a population is determined by a balance between the selective advantage 
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conferred by the mutated alleles in the presence of the drug and natural purifying selection 
eliminating mutations that incur fitness cost in absence of the drug [70]. There are a number 
of observations indicating that mutations associated with drug resistance indeed reduce the 
parasites’ fitness in absence of drug pressure. Experimental support comes from an in vitro 
competition experiment showing a reduced survival of drug resistant compared to sensitive 
parasites, when drug pressure was removed [71]. Similar results were observed in competition 
experiments in mice where a pyrimethamine resistant Toxoplasma gondii strain was found to 
have a fitness defect over a sensitive strain [72] or where a drug resistant P. chabaudi clone 
was completely suppressed by a sensitive clone in absence of drug pressure [73].  
 
Evidence from field studies comes from longitudinal surveys reporting temporal fluctuations 
in the frequency of mutations in the genes pfcrt and pfmdr1 [74-76]. Inter-seasonal analysis 
revealed in all studies an increased frequency of the mutant alleles towards the end of the 
rainy and beginning of the subsequent dry season and a decrease in prevalence of mutant 
alleles over the time of the dry season resulting in an increased proportion of sensitive strains 
at the beginning of the ensuing wet season. A likely explanation for the observed pattern is a 
seasonal variation in drug pressure which is high during the wet season, but virtually absent 
during the dry season. The increased number of sensitive strains in absence of drug pressure 
towards the end of the dry season is likely the result of an impaired fitness of resistant 
parasites compared to sensitive ones.  
 
A study in Hainan, China, found the prevalence of chloroquine-resistant P. falciparum strains 
to decrease after abolishment of CQ as first-line treatment [77]. The frequency of the 
resistance marker pfcrt 76T decreased from 90% in 1978 to 54% in 2001. Similarly, re-
emergence of sensitive parasites after suspension of CQ as first line treatment has also been 
reported from Malawi [78], where a progressive decline in the prevalence of pfcrt 76T was 
observed from 85% to 13% between 1992 and 2000. Mita et al. [79] gave evidence that the 
recovery of CQ sensitive parasites in Malawi was due to expansion of the wild type allele 
rather than due to back mutation in the pfcrt gene. 
 
Recent studies have reported a selection of the pfcrt K76 wild type allele [80] and the pfmdr1 
wild type alleles N86, F184 and D1246 following treatment with the artemisinin combination 
therapy Coartem® (artemether-lumefantrine) [80-85]. Therefore, Coartem® seems to be an 
ideal replacement for CQ as a first line-treatment in areas with high levels of CQ resistance. 
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It’s likely that a faster reversal of drug resistance against CQ is achieved through Coartem® 
treatment compared to the situation in absence of treatment.  
 
Estimating the reduction in parasite fitness is desirable as it remains a crucial parameter for 
epidemiological models that aim at predicting the transmission dynamics of malaria and the 
spread of drug resistance. Gaining further knowledge on the extent of fitness loss in drug 
resistant parasites will increase the prediction power of mathematical models [70,86-88]. In 
the future, models predicting the spread or elimination of drug resistance genotypes could be 
applied for guidance of treatment policies and strategies for control of drug resistance. The 
estimation of costs of resistance can also play a major role in making predictions about the re-
emergence of sensitive parasite strains after a particular drug had been suspended. 
 
The fitness of parasites determines their survival in the host or vector and their reproductive 
success. One key factor of fitness is thus the transmission rate to a new host, which is 
represented by the basic reproductive number (R0). In the case of malaria several parameters 
need to be measured in order to determine R0. Among these is for example the infectiousness 
from humans to mosquitoes, the duration of infection in the human host, the probability that 
the mosquito survives the development of the parasite, the infectiousness from mosquitoes to 
humans etc. (summarized in [87]). However, measuring the actual transmission from one host 
to another is experimentally very difficult. Thus, surrogate markers for parasite fitness are 
needed in order to estimate fitness costs of drug resistance. Since experimental infections are 
impossible for ethical reasons and symptomatic infections require immediate treatment, all 
studies of fitness costs in the human host must be restricted to chronic, asymptomatic 
infections in semi-immune hosts in a malaria endemic setting. Parameters of infection 
dynamics such as the duration of infection or the clearance rate might be suitable markers as 
they are considered important parameters to contribute to transmission success of parasites.  
 
This PhD project attempted to identify and measure malariological parameters that might be 
useful for estimating the transmission success of drug resistant parasites. The molecular 
typing data used for determination of these parameters derived from two longitudinal studies 
conducted in the years 2003- 2005 and 2006-2007 in PNG. 
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Rationale 
I. Determination of molecular parameters of infection dynamics by longitudinal 
sampling 
The present study sought to assess the infection dynamics of P. falciparum clones in a 
prospective longitudinal survey in children between 1 and 4.5 years of age that were subject 
to repeated blood sampling over a period of 16 months. Molecular genotyping of consecutive 
blood samples from individual hosts is thought to provide important measures of infection 
dynamics such as the infection and clearance rate or the duration of individual parasite clones 
which might lead to further insights into the acquisition of natural immunity.  
 
Following up our cohort of 269 children provided numerous samples from each individual to 
describe the infection and clearance rate or the duration of infection as baseline measures for 
further analysis. Optimization of sampling strategies was attempted because previous studies 
had reported considerable fluctuations of genotypes in samples collected in daily or short term 
intervals [89,90], which implicates that parasite detection in a single sample is imperfect and 
only partly represents the total parasite population in a host. In order to overcome this 
limitation, we collected 2 consecutive blood samples taken 24 hours apart from each 
individual at regular follow-up visits. This study design allowed estimating the detectability 
of parasite clones and made it possible to assess the benefit obtained by collecting short term 
samples in a large cohort study.  
 
II: Infection dynamics parameters used as surrogate markers for parasite fitness. 
In absence of drug pressure, mutations are thought to incur fitness costs to the parasite. There 
is some evidence from in vitro, but also in vivo studies that mutations associated with drug 
resistance are costly when the usage of specific drugs is abolished. Recently the first attempt 
to quantify the loss of fitness in vivo in the human host was published [91]. This approach was 
based on the reduction of pfcrt76 mutant allele frequency after the abolishment of CQ 
treatment over a period of 13 years. Our assumption is that fitness costs can be measured as 
effects on parasite survival in the host. Therefore parameters of infection dynamics such as 
the ‘duration of infection’ or the ‘clearance rate’ might be useful surrogate markers to 
estimate the loss of fitness caused by drug resistance mutation. If these assumptions were true 
one would expect to find a different genetic make-up of markers associated with drug 
resistance between long-lasting infections and infections that are rapidly cleared by the human 
host. A first indication whether this approach is suitable can be obtained by comparing newly 
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acquired infections and infections from adults, which have previously been shown to carry 
long lasting, chronic infections [35]. This approach will be followed in samples from a 
“treatment to reinfection study” conducted in 2004/2005 where new genotypes can be easily 
identified.  
 
In a further step, more accurate estimates can be gained using a similar approach based on the 
measures of infection dynamics from our longitudinal cohort, as detailed information on the 
persistence of individual parasite clones are available from these data. A great advantage of 
our study site in PNG compared to highly endemic areas in Africa is the overall low 
multiplicity of infection. In PNG most individuals harbour single clone infections ([92] and 
own data) which makes it possible to clearly assign a drug resistance haplotype to an infecting 
parasite clone and therefore to study the effect of drug resistance mutations on the parasite 
survival within the host.  
 
III Infection dynamics parameters used to determine risk factors for clinical episodes 
Since the age group studied in our longitudinal survey is most susceptible to clinical malaria 
episodes, our study provides optimal conditions to investigate changes in the actually 
infecting genotypes when children develop symptomatic episodes. As indicated previously, 
morbid episodes occur when children acquire new parasite clones [89,90]. Our study design 
made it possible to compare genotypes of a sample set collected from clinical cases and 
compare these to samples collected in the preceding asymptomatic phase of each child. This 
study design also allows the definition of risk factors for a clinical malaria episode such as 
effects of concurrent infections, i.e. a different Plasmodium species or multiplicity of P. 
falciparum infections.  
 
Objectives 
I. Describe the infection dynamics of P. falciparum by molecular typing in our longitudinal 
survey of 269 children in Papua New Guinea. 
II. Determine and apply parameters of infection dynamics to estimate the fitness costs 
incurred by mutations associate with drug resistance, in vivo.  
III. Investigate the genetic profile of samples derived from clinical episodes to define risk 
factors for malaria morbidity. 
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The specific objectives of this project were as follows:  
 
I.1.  To estimate the detectability of infection in a large set of samples collected 24 
hours apart, and to investigate the benefit obtained by collecting 24 hour bleeds 
for our longitudinal study.   
 
I.2.  To describe the parasite population of a longitudinal cohort in children from 
Papua New Guinea and to determine acquisition rates, clearance rates and 
duration of infections as essential parameters describing infections dynamics. 
 
I.3. To develop a new protocol for high resolution genotyping of the polymorphic 
marker gene merozoite surface protein 1 (msp1) by capillary electrophoresis in 
order to improve discrimination of individual parasite clones during 
longitudinal tracking of an infection. 
 
 
II.1. To compare the genetic profile of known markers of drug resistance between 
new infections after radical cure and infections from adults from a cross 
sectional study where measurements of clone persistence are absent, assuming 
that adults harbour chronic infections.  
 
II.2. To compare the genetic profile of known markers of drug resistance between 
new infections and persisting infections of known duration. 
 
 
III.1. To determine the genetic profile in samples from clinical episodes as compared 
to samples from asymptomatic carriage in order to investigate whether 
symptoms are caused by newly acquired parasites strains and whether co-
infections with other strains or Plasmodium species protect against morbidity.  
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Study design and population 
 
Under the auspices of the Institute of Medical Research in Papua New Guinea (PNG IMR) 
and in collaboration with Case Western Reserve University (USA) a prospective longitudinal 
survey was conducted in the Maprik district, East Sepik Province, PNG. A cohort of 269 
children 12 to 36 months (± 1 month) of age at enrolment was followed-up over 16 months 
from March 2006 until July 2007. All study participants were recruited from 10 different 
villages in the vicinity of Ilahita health centre (HC) (Figure 1). 
 
 
 
Figure 1: Study location – The Ilahita area, East Sepik Province, Papua New Guinea. This 
map was kindly provided by Ivo Müller.  
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Enrolment was conducted during a period of two weeks. A clinical examination was 
performed for each child after obtaining written informed consent from parents or legal 
guardians and each child was assessed for inclusion / exclusion criteria. A 5ml venous blood 
sample was collected and a case report form was completed to document a unique study 
identification number, demographic information as well as reported history of illness, 
antimalarial treatments and bednet usage of each child. Since the expected number of children 
could not be reached during the first 2 weeks of enrolment, further children were still included 
into the study at later follow-up visits until the number of participants we aimed at was 
reached. 
 
 
Figure 2: Schematic presentation of the study design  
 Enrolment visit 
 Follow-up bleed (FUB) visits on two consecutive days 
 Clinical follow-up visit in two-weekly intervals 
HC health centre 
Hb haemoglobin 
* Spleen size was determined according to Hacket’s grading.  
 
 
Active follow-up consisted of biweekly clinical follow-up visits and 8 weekly follow-up bleed 
(FUB) visits. The design of the study is demonstrated schematically in Figure 2. At the two-
weekly morbidity surveillance visits, a short physical examination was performed and the 
history of symptoms in the preceding 2 weeks was recorded. In case a study participant 
presented with a presumptive malaria infection, a blood slide and a finger-prick blood sample 
(250µl) were collected and a rapid diagnostic test (RDT) was performed. Upon positive RDT 
and/or blood slide, antimalarial treatment with Coartem® (Novartis, Switzerland) was initiated 
Venous bleed   
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(24h apart) 
 
       
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(24h apart) 
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Study visits 
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Clinical 
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HC surveillance 
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by a medically trained staff. At the 8-weekly FUB visits the study team collected 2 finger-
prick blood samples 24 hours apart and recorded the spleen size and haemoglobin (Hb) level 
of each child. In case of malaria symptoms and/or a positive RDT or in case of moderate-to-
severe anaemia (Hb <7.5 g/dL), antimalarial treatment with Coartam® was initiated. At the 
final study visit another 5ml venous blood sample was collected. A passive case detection 
system was set up at the Ilahita Health Centre, where a team nurse was based during the entire 
period of the study. Whenever a participating child presented at the local HC with a febrile 
illness, a case report form was completed, a finger-prick blood sample and a blood slide 
collected, a RDT performed and the Hb level was measured. Similar to the regular follow-up 
visits, antimalarial treatment was administered upon positive RDT and/or blood slide or in 
case of moderate-to-severe anaemia.  
 
 
Ethical considerations 
 
This study was conducted according to the Declaration of Helsinki and in compliance with 
Good Clinical Practice (ICH GCP E6) regulations and guidelines. The study was approved by 
the Institutional Review Boards of the PNGIMR (PNG Medical Research Advisory 
Committee) and Cleveland Hospital IRB and the Ethikkommission beider Basel (EKBB). 
 
Prior to recruitment of study participants, community information meetings were held where 
the purpose of the study and the detailed study procedures were explained to the village 
population. Written informed consent was sought from parents or legal guardians prior to first 
sample collection. Participants were informed about their right to withdraw from the study at 
any time point. In order to protect confidentiality participant information were identified by a 
unique study identification number and/or blood sampling code and serial number. Databases 
were made anonymous to eliminate any variables that allowed identification of individual 
participants. 
 
Children which were discontinued from the study due to development of chronic illness were 
offered continuous participation in the biweekly morbidity surveillance visits and medical 
advice from the study team.  
 
CHAPTER 1: INTRODUCTION 
 29 
Reference list 
 
 1.  World Health Organization: Country Health Information Profiles. 2006. 
 2.  Genton B, al-Yaman F, Beck HP, Hii J, Mellor S, Narara A, Gibson N, Smith T, 
Alpers MP: The epidemiology of malaria in the Wosera area, East Sepik Province, 
Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices 
and immunity. Ann Trop Med Parasitol 1995, 89: 359-376. 
 3.  Cattani JA, Tulloch JL, Vrbova H, Jolley D, Gibson FD, Moir JS, Heywood PF, 
Alpers MP, Stevenson A, Clancy R: The epidemiology of malaria in a population 
surrounding Madang, Papua New Guinea. Am J Trop Med Hyg 1986, 35: 3-15. 
 4.  Cox MJ, Kum DE, Tavul L, Narara A, Raiko A, Baisor M, Alpers MP, Medley GF, 
Day KP: Dynamics of malaria parasitaemia associated with febrile illness in 
children from a rural area of Madang, Papua New Guinea. Trans R Soc Trop Med 
Hyg 1994, 88: 191-197. 
 5.  Mueller I, Bjorge S, Poigeno G, Kundi J, Tandrapah T, Riley ID, Reeder JC: The 
epidemiology of malaria in the Papua New Guinea highlands: 2. Eastern 
Highlands Province. P N G Med J 2003, 46: 166-179. 
 6.  Mueller I, Kundi J, Bjorge S, Namuigi P, Saleu G, Riley ID, Reeder JC: The 
epidemiology of malaria in the Papua New Guinea highlands: 3. Simbu Province. 
P N G Med J 2004, 47: 159-173. 
 7.  Mueller I, Namuigi P, Kundi J, Ivivi R, Tandrapah T, Bjorge S, Reeder JC: Epidemic 
malaria in the highlands of Papua New Guinea. Am J Trop Med Hyg 2005, 72: 
554-560. 
 8.  Hii J, Dyke T, Dagoro H, Sanders RC: Health impact assessments of malaria and 
Ross River virus infection in the Southern Highlands Province of Papua New 
Guinea. P N G Med J 1997, 40: 14-25. 
 9.  Mueller I, Taime J, Ivivi R, Yala S, Bjorge S, Riley ID, Reeder JC: The epidemiology 
of malaria in the Papua New Guinea highlands: 1. Western Highlands Province. 
P N G Med J 2003, 46: 16-31. 
 10.  Mueller I, Ousari M, Yala S, Ivivi R, Sie A, Reeder JC: The epidemiology of malaria 
in the Papua New Guinea highlands: 4. Enga Province. P N G Med J 2006, 49: 
115-125. 
 11.  Mueller I, Yala S, Ousari M, Kundi J, Ivivi R, Saleu G, Sie A, Saleu G, Reeder JC: 
The epidemiology of malaria in the Papua New Guinea highlands: 6. Simbai and 
Bundi, Madang Province. P N G Med J 2007, 50: 123-133. 
 12.  Mueller I, Sie A, Ousari M, Iga J, Yala S, Ivivi R, Reeder JC: The epidemiology of 
malaria in the Papua New Guinea highlands: 5. Aseki, Menyamya and Wau-
Bulolo, Morobe Province. P N G Med J 2007, 50: 111-122. 
 13.  al-Yaman F, Genton B, Reeder JC, Anders RF, Smith T, Alpers MP: Reduced risk of 
clinical malaria in children infected with multiple clones of Plasmodium 
CHAPTER 1: INTRODUCTION 
 30 
falciparum in a highly endemic area: a prospective community study. Trans R Soc 
Trop Med Hyg 1997, 91: 602-605. 
 14.  Genton B, al-Yaman F, Beck HP, Hii J, Mellor S, Rare L, Ginny M, Smith T, Alpers 
MP: The epidemiology of malaria in the Wosera area, East Sepik Province, 
Papua New Guinea, in preparation for vaccine trials. II. Mortality and 
morbidity. Ann Trop Med Parasitol 1995, 89: 377-390. 
 15.  Kasehagen LJ, Mueller I, McNamara DT, Bockarie MJ, Kiniboro B, Rare L, Lorry K, 
Kastens W, Reeder JC, Kazura JW, Zimmerman PA: Changing patterns of 
Plasmodium blood-stage infections in the Wosera region of Papua New Guinea 
monitored by light microscopy and high throughput PCR diagnosis. Am J Trop 
Med Hyg 2006, 75: 588-596. 
 16.  Smith T, Genton B, Baea K, Gibson N, Taime J, Narara A, al-Yaman F, Beck HP, Hii 
J, Alpers M: Relationships between Plasmodium falciparum infection and 
morbidity in a highly endemic area. Parasitology 1994, 109 ( Pt 5): 539-549. 
 17.  Muller I, Bockarie M, Alpers M, Smith T: The epidemiology of malaria in Papua 
New Guinea. Trends Parasitol 2003, 19: 253-259. 
 18.  Mehlotra RK, Lorry K, Kastens W, Miller SM, Alpers MP, Bockarie M, Kazura JW, 
Zimmerman PA: Random distribution of mixed species malaria infections in 
Papua New Guinea. Am J Trop Med Hyg 2000, 62: 225-231. 
 19.  Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, Susapu M, Tarongka N, 
Zimmerman PA, Reeder JC, Beeson JG, Schofield L, King CL, Mueller I: The risk of 
malarial infections and disease in Papua New Guinean children. Am J Trop Med 
Hyg 2007, 76: 997-1008. 
 20.  Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Muller I: 
Plasmodium vivax and mixed infections are associated with severe malaria in 
children: a prospective cohort study from Papua New Guinea. PLoS Med 2008, 5: 
e127. 
 21.  Smith T, Genton B, Baea K, Gibson N, Narara A, Alpers MP: Prospective risk of 
morbidity in relation to malaria infection in an area of high endemicity of 
multiple species of Plasmodium. Am J Trop Med Hyg 2001, 64: 262-267. 
 22.  Sapak P, Garner P, Baea M, Narara A, Heywood P, Alpers M: Ineffectiveness of 
amodiaquine against Plasmodium falciparum malaria in symptomatic young 
children living in an endemic malarious area of Papua New Guinea. J Trop 
Pediatr 1991, 37: 185-190. 
 23.  Genton B, Baea K, Lorry K, Ginny M, Wines B, Alpers MP: Parasitological and 
clinical efficacy of standard treatment regimens against Plasmodium falciparum, 
P. vivax and P. malariae in Papua New Guinea. P N G Med J 2005, 48: 141-150. 
 24.  al-Yaman F, Genton B, Mokela D, Narara A, Raiko A, Alpers MP: Resistance of 
Plasmodium falciparum malaria to amodiaquine, chloroquine and quinine in the 
Madang Province of Papua New Guinea, 1990-1993. P N G Med J 1996, 39: 16-22. 
CHAPTER 1: INTRODUCTION 
 31 
 25.  Dulay IS, Gibson FD, Eyeson-Annan MB, Narara A: Chloroquine resistance in 
Plasmodium falciparum and its geographical distribution in Papua New Guinea. 
P N G Med J 1987, 30: 281-290. 
 26.  Marfurt J, Mueller I, Sie A, Maku P, Goroti M, Reeder JC, Beck HP, Genton B: Low 
efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against 
Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop 
Med Hyg 2007, 77: 947-954. 
 27.  World Health Organization: Guidelines for the Treatment of Malaria. 2006. 
 28.  Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, Oa O, Griffin S, 
Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, 
Siba P, Ilett KF, Davis TM: A trial of combination antimalarial therapies in 
children from Papua New Guinea. N Engl J Med 2008, 359: 2545-2557. 
 29.  Smythe JA, Peterson MG, Coppel RL, Saul AJ, Kemp DJ, Anders RF: Structural 
diversity in the 45-kilodalton merozoite surface antigen of Plasmodium 
falciparum. Mol Biochem Parasitol 1990, 39: 227-234. 
 30.  Miller LH, Roberts T, Shahabuddin M, McCutchan TF: Analysis of sequence 
diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). 
Mol Biochem Parasitol 1993, 59: 1-14. 
 31.  Snounou G, White NJ: The co-existence of Plasmodium: sidelights from 
falciparum and vivax malaria in Thailand. Trends Parasitol 2004, 20: 333-339. 
 32.  Ntoumi F, Contamin H, Rogier C, Bonnefoy S, Trape JF, Mercereau-Puijalon O: Age-
dependent carriage of multiple Plasmodium falciparum merozoite surface 
antigen-2 alleles in asymptomatic malaria infections. Am J Trop Med Hyg 1995, 
52: 81-88. 
 33.  Felger I, Tavul L, Beck HP: Plasmodium falciparum: a rapid technique for 
genotyping the merozoite surface protein 2. Exp Parasitol 1993, 77: 372-375. 
 34.  Felger I, Beck HP: Genotyping of Plasmodium falciparum. PCR-RFLP analysis. 
Methods Mol Med 2002, 72: 117-129. 
 35.  Falk N, Maire N, Sama W, Owusu-Agyei S, Smith T, Beck HP, Felger I: Comparison 
of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics 
of Plasmodium falciparum. Am J Trop Med Hyg 2006, 74: 944-950. 
 36.  Jafari S, Le BJ, Bouchaud O, Durand R: Plasmodium falciparum clonal population 
dynamics during malaria treatment. J Infect Dis 2004, 189: 195-203. 
 37.  Arnot D: Unstable malaria in Sudan: the influence of the dry season. Clone 
multiplicity of Plasmodium falciparum infections in individuals exposed to 
variable levels of disease transmission. Trans R Soc Trop Med Hyg 1998, 92: 580-
585. 
 38.  Konate L, Zwetyenga J, Rogier C, Bischoff E, Fontenille D, Tall A, Spiegel A, Trape 
JF, Mercereau-Puijalon O: Variation of Plasmodium falciparum msp1 block 2 and 
msp2 allele prevalence and of infection complexity in two neighbouring 
CHAPTER 1: INTRODUCTION 
 32 
Senegalese villages with different transmission conditions. Trans R Soc Trop Med 
Hyg 1999, 93 Suppl 1: 21-28. 
 39.  Smith T, Beck HP, Kitua A, Mwankusye S, Felger I, Fraser-Hurt N, Irion A, Alonso 
P, Teuscher T, Tanner M: Age dependence of the multiplicity of Plasmodium 
falciparum infections and of other malariological indices in an area of high 
endemicity. Trans R Soc Trop Med Hyg 1999, 93 Suppl 1: 15-20. 
 40.  Farnert A, Snounou G, Rooth I, Bjorkman A: Daily dynamics of Plasmodium 
falciparum subpopulations in asymptomatic children in a holoendemic area. Am J 
Trop Med Hyg 1997, 56: 538-547. 
 41.  Daubersies P, Sallenave-Sales S, Magne S, Trape JF, Contamin H, Fandeur T, Rogier 
C, Mercereau-Puijalon O, Druilhe P: Rapid turnover of Plasmodium falciparum 
populations in asymptomatic individuals living in a high transmission area. Am J 
Trop Med Hyg 1996, 54: 18-26. 
 42.  Felger I, Smith T, Edoh D, Kitua A, Alonso P, Tanner M, Beck HP: Multiple 
Plasmodium falciparum infections in Tanzanian infants. Trans R Soc Trop Med 
Hyg 1999, 93 Suppl 1: 29-34. 
 43.  Mayor A, Saute F, Aponte JJ, Almeda J, Gomez-Olive FX, Dgedge M, Alonso PL: 
Plasmodium falciparum multiple infections in Mozambique, its relation to other 
malariological indices and to prospective risk of malaria morbidity. Trop Med Int 
Health 2003, 8: 3-11. 
 44.  Farnert A, Rooth I, Svensson, Snounou G, Bjorkman A: Complexity of Plasmodium 
falciparum infections is consistent over time and protects against clinical disease 
in Tanzanian children. J Infect Dis 1999, 179: 989-995. 
 45.  Muller DA, Charlwood JD, Felger I, Ferreira C, do R, V, Smith T: Prospective risk 
of morbidity in relation to multiplicity of infection with Plasmodium falciparum 
in Sao Tome. Acta Trop 2001, 78: 155-162. 
 46.  McKenzie FE, Bossert WH: Mixed-species Plasmodium infections of humans. J 
Parasitol 1997, 83: 593-600. 
 47.  Bruce MC, Day KP: Cross-species regulation of Plasmodium parasitemia in semi-
immune children from Papua New Guinea. Trends Parasitol 2003, 19: 271-277. 
 48.  Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ: The 
epidemiology of severe malaria in an area of low transmission in Thailand. Trans 
R Soc Trop Med Hyg 1997, 91: 256-262. 
 49.  Sidhu AB, Verdier-Pinard D, Fidock DA: Chloroquine resistance in Plasmodium 
falciparum malaria parasites conferred by pfcrt mutations. Science 2002, 298: 
210-213. 
 50.  Babiker HA, Pringle SJ, bdel-Muhsin A, Mackinnon M, Hunt P, Walliker D: High-
level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is 
associated with mutations in the chloroquine resistance transporter gene pfcrt 
and the multidrug resistance Gene pfmdr1. J Infect Dis 2001, 183: 1535-1538. 
CHAPTER 1: INTRODUCTION 
 33 
 51.  Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su 
XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D: A molecular 
marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001, 344: 
257-263. 
 52.  Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GA, 
Greenwood BM, Warhurst DC: Evidence for selection for the tyrosine-86 allele of 
the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquine. 
Parasitology 1997, 114 ( Pt 3): 205-211. 
 53.  Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ, Cowman AF: 
Several alleles of the multidrug-resistance gene are closely linked to chloroquine 
resistance in Plasmodium falciparum. Nature 1990, 345: 255-258. 
 54.  Dorsey G, Kamya MR, Singh A, Rosenthal PJ: Polymorphisms in the Plasmodium 
falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in 
Kampala, Uganda. J Infect Dis 2001, 183: 1417-1420. 
 55.  Basco LK, Ringwald P: pfmdr1 gene mutation and clinical response to 
chloroquine in Yaounde, Cameroon. Trans R Soc Trop Med Hyg 1997, 91: 210-211. 
 56.  Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF: Pgh1 modulates sensitivity 
and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000, 
403: 906-909. 
 57.  Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, 
Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK: 
Mutations in Plasmodium falciparum dihydrofolate reductase and 
dihydropteroate synthase and epidemiologic patterns of pyrimethamine-
sulfadoxine use and resistance. J Infect Dis 1997, 176: 1590-1596. 
 58.  Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ: Amino acid changes linked 
to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase 
gene of Plasmodium falciparum. Proc Natl Acad Sci U S A 1988, 85: 9109-9113. 
 59.  Basco LK, Ringwald P: Molecular epidemiology of malaria in Yaounde, 
Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate 
reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine 
and cycloguanil. Am J Trop Med Hyg 2000, 62: 271-276. 
 60.  Wu Y, Kirkman LA, Wellems TE: Transformation of Plasmodium falciparum 
malaria parasites by homologous integration of plasmids that confer resistance to 
pyrimethamine. Proc Natl Acad Sci U S A 1996, 93: 1130-1134. 
 61.  Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF: Allelic exchange at the 
endogenous genomic locus in Plasmodium falciparum proves the role of 
dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J 1998, 17: 
3807-3815. 
 62.  Wang P, Read M, Sims PF, Hyde JE: Sulfadoxine resistance in the human malaria 
parasite Plasmodium falciparum is determined by mutations in dihydropteroate 
synthetase and an additional factor associated with folate utilization. Mol 
Microbiol 1997, 23: 979-986. 
CHAPTER 1: INTRODUCTION 
 34 
 63.  Triglia T, Menting JG, Wilson C, Cowman AF: Mutations in dihydropteroate 
synthase are responsible for sulfone and sulfonamide resistance in Plasmodium 
falciparum. Proc Natl Acad Sci U S A 1997, 94: 13944-13949. 
 64.  Basco LK, Tahar R, Keundjian A, Ringwald P: Sequence variations in the genes 
encoding dihydropteroate synthase and dihydrofolate reductase and clinical 
response to sulfadoxine-pyrimethamine in patients with acute uncomplicated 
falciparum malaria. J Infect Dis 2000, 182: 624-628. 
 65.  Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G, Dao LD, Mshinda 
H, Tanner M, Watkins WM, Sims PF, Hyde JE: Resistance to antifolates in 
Plasmodium falciparum monitored by sequence analysis of dihydropteroate 
synthetase and dihydrofolate reductase alleles in a large number of field samples 
of diverse origins. Mol Biochem Parasitol 1997, 89: 161-177. 
 66.  Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, 
Esterre P, Fandeur T, Mercereau-Puijalon O: Resistance of Plasmodium falciparum 
field isolates to in-vitro artemether and point mutations of the SERCA-type 
PfATPase6. Lancet 2005, 366: 1960-1963. 
 67.  Eckstein-Ludwig U, Webb RJ, Van G, I, East JM, Lee AG, Kimura M, O'Neill PM, 
Bray PG, Ward SA, Krishna S: Artemisinins target the SERCA of Plasmodium 
falciparum. Nature 2003, 424: 957-961. 
 68.  Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, Zuniga FA, 
East M, Lee A, Brady L, Haynes RK, Krishna S: A single amino acid residue can 
determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol 2005, 12: 
628-629. 
 69.  Wernsdorfer WH: The development and spread of drug-resistant malaria. 
Parasitol Today 1991, 7: 297-303. 
 70.  Hastings IM: A model for the origins and spread of drug-resistant malaria. 
Parasitology 1997, 115 ( Pt 2): 133-141. 
 71.  Hayward R, Saliba KJ, Kirk K: pfmdr1 mutations associated with chloroquine 
resistance incur a fitness cost in Plasmodium falciparum. Mol Microbiol 2005, 55: 
1285-1295. 
 72.  Fohl LM, Roos DS: Fitness effects of DHFR-TS mutations associated with 
pyrimethamine resistance in apicomplexan parasites. Mol Microbiol 2003, 50: 
1319-1327. 
 73.  de Roode JC, Culleton R, Bell AS, Read AF: Competitive release of drug resistance 
following drug treatment of mixed Plasmodium chabaudi infections. Malar J 
2004, 3: 33. 
 74.  Abdel-Muhsin AM, Mackinnon MJ, Ali E, Nassir e, Suleiman S, Ahmed S, Walliker 
D, Babiker HA: Evolution of drug-resistance genes in Plasmodium falciparum in 
an area of seasonal malaria transmission in Eastern Sudan. J Infect Dis 2004, 189: 
1239-1244. 
CHAPTER 1: INTRODUCTION 
 35 
 75.  Babiker HA, Satti G, Ferguson H, Bayoumi R, Walliker D: Drug resistant 
Plasmodium falciparum in an area of seasonal transmission. Acta Trop 2005, 94: 
260-268. 
 76.  Ord R, Alexander N, Dunyo S, Hallett R, Jawara M, Targett G, Drakeley CJ, 
Sutherland CJ: Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian 
Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. 
J Infect Dis 2007, 196: 1613-1619. 
 77.  Wang X, Mu J, Li G, Chen P, Guo X, Fu L, Chen L, Su X, Wellems TE: Decreased 
prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T 
marker associated with cessation of chloroquine use against P. falciparum 
malaria in Hainan, People's Republic of China. Am J Trop Med Hyg 2005, 72: 410-
414. 
 78.  Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde 
AA, Kouriba B, Taylor TE, Plowe CV: Reemergence of chloroquine-sensitive 
Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J 
Infect Dis 2003, 187: 1870-1875. 
 79.  Mita T, Kaneko A, Lum JK, Zungu IL, Tsukahara T, Eto H, Kobayakawa T, 
Bjorkman A, Tanabe K: Expansion of wild type allele rather than back mutation 
in pfcrt explains the recent recovery of chloroquine sensitivity of Plasmodium 
falciparum in Malawi. Mol Biochem Parasitol 2004, 135: 159-163. 
 80.  Sisowath C, Petersen I, Veiga MI, Martensson A, Premji Z, Bjorkman A, Fidock DA, 
Gil JP: In vivo selection of Plasmodium falciparum parasites carrying the 
chloroquine-susceptible pfcrt K76 allele after treatment with artemether-
lumefantrine in Africa. J Infect Dis 2009, 199: 750-757. 
 81.  Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G: Selection of 
Plasmodium falciparum pfmdr1 alleles following therapy with artemether-
lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob 
Agents Chemother 2006, 50: 1893-1895. 
 82.  Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O'Neil M, Milhous W, 
Wirth DF, Oduola AM: Selection of Plasmodium falciparum multidrug resistance 
gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in 
Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents 
Chemother 2009, 53: 888-895. 
 83.  Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, Sutherland 
CJ, Hallett RL: Amodiaquine and artemether-lumefantrine select distinct alleles 
of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for 
uncomplicated malaria. Antimicrob Agents Chemother 2007, 51: 991-997. 
 84.  Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP: 
In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by 
artemether-lumefantrine (Coartem). J Infect Dis 2005, 191: 1014-1017. 
 85.  Sisowath C, Ferreira PE, Bustamante LY, Dahlstrom S, Martensson A, Bjorkman A, 
Krishna S, Gil JP: The role of pfmdr1 in Plasmodium falciparum tolerance to 
artemether-lumefantrine in Africa. Trop Med Int Health 2007, 12: 736-742. 
CHAPTER 1: INTRODUCTION 
 36 
 86.  Mackinnon MJ, Hastings IM: The evolution of multiple drug resistance in malaria 
parasites. Trans R Soc Trop Med Hyg 1998, 92: 188-195. 
 87.  Koella JC, Antia R: Epidemiological models for the spread of anti-malarial 
resistance. Malar J 2003, 2: 3. 
 88.  Laxminarayan R: Act now or later? Economics of malaria resistance. Am J Trop 
Med Hyg 2004, 71: 187-195. 
 89.  Contamin H, Fandeur T, Rogier C, Bonnefoy S, Konate L, Trape JF, Mercereau-
Puijalon O: Different genetic characteristics of Plasmodium falciparum isolates 
collected during successive clinical malaria episodes in Senegalese children. Am J 
Trop Med Hyg 1996, 54: 632-643. 
 90.  Kun JF, Missinou MA, Lell B, Sovric M, Knoop H, Bojowald B, Dangelmaier O, 
Kremsner PG: New emerging Plasmodium falciparum genotypes in children 
during the transition phase from asymptomatic parasitemia to malaria. Am J 
Trop Med Hyg 2002, 66: 653-658. 
 91.  Mwai L, Ochong E, Abdirahman A, Kiara SM, Ward S, Kokwaro G, Sasi P, Marsh K, 
Borrmann S, Mackinnon M, Nzila A: Chloroquine resistance before and after its 
withdrawal in Kenya. Malar J 2009, 8: 106. 
 92.  Marfurt J, Muller I, Sie A, Oa O, Reeder JC, Smith TA, Beck HP, Genton B: The 
usefulness of twenty-four molecular markers in predicting treatment outcome 
with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine 
against falciparum malaria in Papua New Guinea. Malar J 2008, 7: 61. 
 
CHAPTER 1: INTRODUCTION 
 37 
Thesis outline 
 
The following 5 chapters correspond to individual publications that are already published or 
will be submitted to the mentioned scientific journals: 
 
 
Chapter 2: “Heterogeneous distribution of Plasmodium falciparum drug resistance haplotypes 
in subsets of the host population”; Malar J. 2008 May 6;7:78. 
 
Chapter 3: “Comparison of Plasmodium falciparum allelic frequency distributions in different 
endemic settings by high resolution genotyping”; to be submitted to the Malaria Journal.  
 
Chapter 4: “Treatment with Coartem® (artemether-lumefantrine) in Papua New Guinea”; 
submitted to the American Journal of Tropical Medicine and Hygiene.  
 
Chapter 5: “Estimates of Detectability of P. falciparum and Force of Infection based on 
molecular data”; to be submitted to PLoS ONE. 
 
Chapter 6: “Parasitological risk factors for Plasmodium falciparum episodes in Papua New 
Guinean children”; to be submitted to the Malaria Journal after further revisions. 
 
 
 
Annex papers 
In the course of this thesis contributions were made to additional publications which are not 
directly linked to the main part of this thesis.  
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ABSTRACT 
 
Diversity and complexity of the merozoite surface proteins 1 and 2 (msp1 and msp2) of P. 
falciparum infections were investigated in different malaria transmission settings. We applied 
a high resolution capillary electrophoresis based technique to genotype samples from Papua 
New Guinea and Tanzania. We compared the results to previous work based on low 
resolution genotyping of PCR fragments on agarose gels to investigate whether more accurate 
sizing generates different results. Our results confirmed previous reports of a higher mean 
multiplicity of infection for both marker genes and increased genetic diversity as estimated by 
the total number of distinct alleles for msp2 in areas of higher endemicity. For msp1 alone a 
minor increase in diversity was observed. Measures of between population variance in allele 
frequencies (FST) indicated little genetic differentiation for both marker genes between the 
two populations in different endemic settings. The mean multiplicity of infection (MOI) 
adjusted for the probability of multiple infections sharing the same allele was estimated by 
using the msp2 allele frequency distribution and the distribution of observed numbers of 
infections. For the high resolution typing technique applied in this study, this adjustment 
made little difference to the estimated mean MOI compared to the observed mean MOI.  
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INTRODUCTION 
 
Plasmodium falciparum populations are highly diverse and individual hosts are often 
simultaneously infected by multiple parasite clones. In order to discriminate parasite clones 
within one host PCR-based genotyping of a number of different marker genes has been 
established. Among these are the merozoite surface proteins 1 and 2 (msp1 and msp2), and the 
glutamate-rich protein (glurp), which show extensive length polymorphism and can therefore 
be distinguished by electrophoresis on agarose or polyacrylamide gels. 
Recently, capillary electrophoresis (CE) based genotyping of msp2 was shown to have a much 
higher discriminatory power than previously applied techniques (Falk et al. 2006). This 
technique has been proven useful in areas of high endemicity where individuals are 
simultaneously infected with many different parasite clones. It has also been useful for 
distinguishing recrudescent from new infections after antimalarial treatment (Jafari et al. 
2004) and in tracking individual parasite clones over time in longitudinal surveys, where 
consecutive blood samples were collected from each individual (Falk et al. 2006). Similar to 
the CE based msp2 genotyping, we have applied a CE protocol for genotyping the 
polymorphic block 2 of the msp1gene  
 
In this study we investigated the impact of transmission intensity on the genetic diversity of 
the two marker genes msp1 and msp2. Most previous studies have shown a greater diversity 
for msp2 in high endemic settings (e.g. Babiker et al. 1997;Hoffmann et al. 2001;Konate et al. 
1999;Paul & Day 1998), but for msp1 conflicting results were reported (e.g. Bendixen et al. 
2001;da Silveira et al. 1999;Ferreira et al. 1998a;Ferreira et al. 1998b;Kaneko et al. 
1997;Konate et al. 1999;Paul & Day 1998;Silva et al. 2000). 
These data all relied on low resolution genotyping consisting of fragment sizing on agarose 
gels with individual genotypes defined as bins of ≥ 20 base pairs. Using this approach several 
distinct fragments may be combined within one genotype bin. Greenhouse et al. ( 2007) 
studied the impact of transmission intensity on the accuracy of genotyping and found that 
with increasing transmission intensity and therefore increasing complexity of infection, 
genotyping becomes less accurate. These finding are not only important for recrudescent-
reinfection typing in antimalarial drug trials but also for assessing the impact of transmission 
intensity on genetic diversity. The authors concluded that a genotyping technique with higher 
discriminatory power is needed for genotyping samples from areas of high transmission 
intensity. We have now applied an improved high resolution genotyping approach to P. 
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falciparum infected samples from Papua New Guinea (PNG) and Tanzania (TZ). These study 
sites differ extensively in their transmission intensity as previously shown by Arnot et al. ( 
1998). We sought to assess whether the previously observed difference in msp1 and mps2 
diversity in different endemic settings is independent of technical approaches or whether more 
sensitive detection of allelic size differences would alter these previous results. For direct 
standardized comparison the same genotyping technique was applied for all samples. 
CHAPTER 3 
 53 
METHODS 
 
The msp1 and msp2 loci were subject to high resolution genotyping in 2 sets of DNA samples 
that had been PCR positive in previous tests. 108 samples from PNG were derived from a 
longitudinal field survey in 1-4 year old children conducted in an area near Maprik, East 
Sepik Province (Lin et al., in preparation). Scientific approval and ethical clearance for the 
study was obtained from the Medical Research and Advisory Committee (MRAC) of the 
Ministry of Health in PNG and from the Ethikkommission beider Basel in Switzerland. 
Informed consent was sought from all parents or guardians prior to recruitment of each child. 
115 Tanzanian samples were derived from the placebo group of a vaccine efficacy trial 
conducted from 1993-1994 in children <5 years of age in the village Idete, which is located in 
the Kilombero District of Morogoro Region, Tanzania (Alonso et al. 1994;Beck et al. 1997)  
 
Prior to PCR amplification of the msp1 and msp2 target sequence, DNA was extracted from 
cell pellets using QIAamp® 96 DNA Blood Kit (Qiagen, Australia) according to the 
manufacturer’s instructions. Msp2 genotyping was performed as previously described by Falk 
et al. ( 2006) with some minor changes and adaptations of PCR conditions for highly purified 
DNA. In brief, primary PCR reaction conditions were adjusted to a final volume of 50µl 
including 2µl of extracted DNA. Cycle conditions for primary PCR were 2 min at 94°C 
followed by 25 cycles of 30 s at 94°C, 45 s at 45°C, 90 s at 70°C, and a final extension at 
70°C for 10min. In order to reduce the carry over of primary PCR primers into the nested 
PCR, only one µl of primary PCR product was amplified in the nested PCR reaction with the 
following cycle conditions: 2 min at 94°C followed by 25 cycles of 30 s at 94°C, 45 s at 50°C, 
90 s at 70°C and a final extension at 70°C for 10 min.  
 
Msp1 occurs as one of three distinct allelic families: K1, MAD20 and RO33. The unique 
family specific sequences K1 and MAD20 flank intragenic repeat units that give rise to 
extensive size polymorphisms, whereas RO33 is not polymorphic. For amplification of the 
polymorphic region of msp1 block 2 (Miller et al. 1993), a nested PCR approach was used. 
Primary PCR was performed in a total volume of 50µl containing 5µl of 10xBufferB (0.8M 
Tris-HCl, 0.2M (NH4)2SO4, 0.2% w/v Tween-20), 2mM MgCl2, 200µM dNTPs, 2.5U Taq 
DNA polymerase (FirePol, Solis BioDyne). Primary PCR primers which are located in the 
conserved sequence spanning the msp1 block2 (M1-OF 5’-
CTAGAAGCTTTAGAAGATGCAGTATTG-3’ and M1-OR 5’-
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CTTAAATAGATTCTAATTCAAGTGGATCA-3’ (Snounou et al. 1999)) were used at a 
final concentration of 300nM each. Two µl of DNA was used as template for this PCR 
reaction. An initial denaturation step of 94°C for 2 min was followed by 30 amplification 
cycles of 30 s at 94°C, 1 min at 54°C, 1 min at 72°C and a final extension for 5 min at 72°C.  
In the nested PCR reaction specific primer pairs were used to amplify the allelic families K1, 
MAD20 and RO33 of msp1 block2. In order to distinguish the size of PCR products by 
capillary electrophoresis, one of the primers for each PCR was labelled with the fluorescent 
dyes VIC, NED or 6-FAM, respectively (Applied Biosystems). Size variations due to 
sporadic addition of adenine by the Taq polymerase at the 3’ end were avoided by adding a 
7bp tail (Applied Biosystems) to the 5’ end of the other primer promoting the additional 
adenine incorporation. Primer sequences for nPCR have previously been published (Snounou 
et al. 1999), but have been modified by fluorescent dyes and 7bp tails: M1-KF 5’-Tail-
AAATGAAGAAGAAATTACTACAAAAGGTGC-3’; M1-KR 5’- NED-
GCTTGCATCAGCTGGAGGGCTTGCACCAGA-3’; M1-MF 5’-Tail-
AAATGAAGGAACAAGTGGAACAGCTGTTAC-3’; M1-MR 5’-6-FAM-
ATCTGAAGGATTTGTACGTCTTGAATTACC-3’. K1 and MAD20 allelic sequences were 
amplified in a duplex nPCR in a total volume of 50µl, containing a final primer concentration 
of 100nM for each primer, 5µl of 10xBufferB (0.8mM Tris-HCl, 0.2M (NH4)2SO4, 0.2% w/v 
Tween-29), 2mM MgCl2, 200µM dNTPs and1.5U Taq DNA polymerase (FirePol, Solis 
BioDyne). 1µl of primary PCR product was used as template for the nested PCR with the 
following conditions: initial denaturation for 2 min at 94°C followed by 35 cycles of 30 s at 
94°C, 1 min at 59°C, 1 min at 72°C and a final extension for 10 min at 72°C. RO33 allelic 
sequences were amplified with primers M1-RF 5’ VIC-
TAAAGGATGGAGCAAATACTCAAGTTGTTG-3’ and the reverse primer M1-R2 5’ Tail-
CAAGTAATTTTGAACTCTATGTTTTAAATCAGCGTA-3’ which is located in the 
conserved region of msp1 block3 and is not family specific. Therefore, RO33 nested PCR was 
run as a separate reaction under the same conditions as described for K1 and MAD20 nested 
PCR. All amplifications were performed on a PTC-100 thermocycler (MJ Research Inc.). 
Nested PCR products were analysed on a 1.5% agarose gel. Depending on the intensity of the 
band, PCR products were diluted 1:5 – 1:40 in H2O. 2.5µl of diluted PCR product was mixed 
with 0.3 µl GeneScan®-500 LIZ® size standard (Applied Biosystems) and 12µl HiDi (highly 
deionized) formamide. The mixture was heated for 5 min at 95°C to separate the double 
strands and then immediately chilled on ice for a few minutes before capillary electrophoresis 
was performed on an AB3130 Sequencer (Applied Biosystems).  
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Data were analysed using the GeneMapper® v3.7 Software (Applied Biosystems). The results 
of size calling were exported as a tab delimited file and imported into an in-house generated 
software which calculated for each sample a cut-off based on the mean height of the size 
standard peaks and grouped all alleles into 3bp bins. For the cut-off, an empirically defined 
constant factor was multiplied by the mean size standard for each sample. This constant factor 
was manually defined after inspecting the background level in single infections. For both 
marker genes the total number of alleles as well as their frequency distributions were 
analysed. The theoretical probability of being infected by two parasites with the same allele 
was calculated as P=∑pi2 where pi is the frequency of allele i (Gatton & Cheng 2008). The 
combined probability that two independent clones share the same genotype for both marker 
genes was calculated by multiplying the probabilities P for both marker genes. As a measure 
for genetic diversity, the expected heterozygosity was calculated by use of the formula 
HE=[n/(n-1)] x [(1-∑pi2)] (Nei 1987), where n is the number of samples and pi the frequency 
of allele i. HE is the probability that two alleles randomly drawn from the population sample 
are different. The mean multiplicity of infection (MOI) was calculated as the total number of 
clones divided by the number of positive samples for each marker gene. Allele frequencies 
were further compared between populations from PNG and TZ using Wright’s F statistics to 
calculate the fixation index FST. FST is a measure of between population variance and gives 
the proportion of overall diversity which is attributable to differences between populations 
(Nei & Chesser 1983). HE and FST values were calculated by Arlequin ver3.1 software 
(Excoffier, Laval, & Schneider 2005). 
We estimated both the frequency distribution and the mean MOI adjusted for the probability 
of multiple infections sharing the same allele using the msp2 allele frequency distribution and 
the distribution of observed numbers of infections according to the method of Ross et al (in 
preparation).  
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RESULTS AND DISCUSSION 
 
The distribution of msp1 and msp2 allele frequencies for 108 Papua New Guinean samples is 
shown in Figure 1. The total number of alleles detected in this sample set is greater for msp2 
than msp1, with 35 vs. 24 differently sized alleles, respectively. The overall genetic diversity 
is also slightly greater for msp2 than msp1 (P=0.07; HE=0.933 for msp2 and P=0.084; 
HE=0.918 for msp1). By combining the two marker genes, the probability that two samples 
share the same genotype by chance can be reduced to 0.0058. Figure 2 shows the allelic 
frequency distribution of msp1 and msp2 in 115 samples from Tanzania. In the Tanzanian 
samples, the total number of msp2 alleles detected by CE was much greater than for msp1 
with 76 vs. 29 alleles discriminated, respectively. The probability P of being infected by two 
parasites with the same allele and the expected heterozygosity values HE showed a greater 
overall diversity for msp2 compared to msp1 (P=0.036; HE=0.965 for msp2 and P=0.085; 
HE=0.917 for msp1) in Tanzanian samples. Combining the two marker genes reduced the 
probability that two samples share the same genotype by chance to 0.003.  
In both countries, msp1 K1 type alleles were the most polymorphic, followed by MAD20 type 
alleles, whereas RO33 was non-polymorphic. For msp2, alleles belonging to the 3D7 family 
showed much more polymorphism than Fc27 type alleles, in both countries (Table 2). For 
msp1, the most dominant alleles were similar between PNG and TZ. For msp2 the most 
frequent allele was the same between the two sites whereas the remaining alleles showed a 
different order of frequency. We compared the variance in allele frequencies between the two 
study sites using Wright’s F statistics. The FST values for pairwise comparisons of allele 
frequencies between population samples were 0.041 for msp1 and 0.017 for msp2, 
respectively (p<0.001 for both markers). These low FST values indicate that allele frequencies 
are highly similar and that there is little genetic differentiation between the investigated 
geographic populations for both marker genes. As previously suggested,  such low FST values 
may indicate that the msp1 and msp2 loci are under balancing selection (Conway 1997), 
increasing the possibility that observed patterns of allele frequencies are the result of 
balancing selection rather than of variation in transmission dynamics.  
 
The quality of genotyping, i.e. optimal differentiation of parasite clones within a blood sample 
and between samples depends on a number of parameters. It is essential that the chosen 
marker gene is highly polymorphic. Many genotyping applications require minimization of 
the probability that two parasites share the same allele by chance. Minimizing this probability 
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is achieved by choosing the most polymorphic marker, but also the allelic frequency 
distribution plays a crucial role and should be homogeneous.  Non-uniform distribution of 
allele frequencies increases the number of distinct alleles required (Gatton & Cheng 2008).  
 
Discrimination can be enhanced by using a second marker gene, which further reduces the 
probability that two samples share the same genotype by chance. In fact, the number of 
marker genes that should be used to adequately discriminate parasites can be different 
between study sites and it has been recommended to choose the number of genes in a way that 
this probability is below 0.05 (Gatton & Cheng 2008). We have shown that in Tanzania, the 
msp2 gene is highly diverse with a total of 76 differently sized alleles, and that the probability 
P of being infected with two parasites sharing the same msp2 genotype is only 3.6%. In 
contrast, the frequency distribution of the msp1 gene in Tanzania is less favourable, since only 
29 alleles could be distinguished and the most common allele has a frequency of >20% . Our 
results suggest that in a high transmission region in Tanzania, where our study was conducted, 
CE genotyping for msp2 alone provided sufficient discrimination power to adequately 
differentiate parasites, since the probability P that two parasites share the same genotype was 
3.6%. For msp1 however, the genetic diversity was not sufficient for use as a single 
genotyping marker. The number of alleles was greater for both marker genes in Tanzanian 
samples than in samples from Papua New Guinea (msp1: 24 vs. 29; msp2: 35vs. 76 in PNG 
vs. TZ, respectively, table 1). Although the overall genetic diversity in PNG was slightly 
greater for msp2 than for msp1 with 35 vs. 24 alleles, the diversity of msp2 in this area was 
not high enough for msp2 to be used as a single marker for genotyping. This is due to a high 
probability (7%) of being infected with two parasites sharing the same allele by chance which 
is above the 5% threshold suggested by Gatton & Cheng ( 2008). Therefore, genotyping of 
both, msp2 and msp1 is required in order to increase discriminatory power in this area. 
Combining the two marker genes reduced the probability that two samples share the same 
genotype by chance to 0.6%. In an area of lower transmission, genotyping two or more 
markers is clearly an option for single clone infections as msp1-msp2 haplotypes are evident.  
But in the case of frequent multiple clone infections this strategy is less beneficial as both 
markers are unlinked and msp1-msp2 haplotypes cannot be determined. This shortfall poses a 
serious handicap if an individual parasite clone needs to be followed up over time in a 
longitudinal series of samples. Other applications, e.g identification of new infections, are 
well suited for combining several markers. 
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Mean MOI was significantly greater in Tanzania than in PNG for both marker genes (msp1: 
1.99 vs. 3.04; p<0.001 and msp2: 1.84 vs. 3.72, p<0.001 for PNG vs. TZ, respectively, table 
1) which confirms previous observations of an increased complexity of infection with 
increasing endemicity (Babiker et al. 1997;Paul et al. 1995). In Tanzanian samples, the mean 
MOI was significantly greater for msp2 than for msp1 (p<0.001), which reflects the great 
difference in the number of distinct alleles between the two allelic families. Despite the fact 
that the number of alleles was also greater for msp2 than for msp1 in PNG, the mean 
multiplicity of infection was slightly higher for msp1, however, this difference was not 
statistically significant. This minor difference in mean MOI might be due to various technical 
reasons like differences in PCR efficiency for the two marker genes, which results in different 
detection limits. Another parameter that influences the number of genotypes per sample is the 
cut-off that is determined for each sample, which is dependent on the internal size standard 
used to control for unequal loading of the PCR product onto the automated sequencer. The 
use of two markers obviously produces minor discrepancies due to technical differences but 
does not affect the overall MOI result.  
 
The results we obtained by applying our high resolution genotyping technique revealed 
similar results to previous reports on allelic diversities in three areas of different malaria 
endemicity in Brazil, Vietnam and Tanzania where the extent of allelic diversity of msp2 as 
estimated by the total number of distinct alleles increased with increasing endemicity 
(Hoffmann et al. 2001). The same populations were also investigated for genetic diversity in 
the msp1 gene. In contrast to msp2, the extent of msp1 diversity did not seem to correlate with 
the level of malaria transmission in these regions (da Silveira et al. 1999;Ferreira et al. 
1998a;Ferreira et al. 1998b;Kaneko et al. 1997;Silva et al. 2000). Our observations of only a 
minor effect of transmission intensity on diversity of msp1 confirmed these previous findings. 
An increased diversity of msp2 in areas of higher endemicity was also reported previously 
(Babiker et al. 1997;Haddad et al. 1999;Konate et al. 1999;Paul & Day 1998), however, most 
of these studies also reported a correlation between endemicity and the number of distinct 
alleles for msp1, which was not the case for the comparison of diversity between Brazil, 
Vietnam and Tanzania and in our study. There were also some studies that did not find a 
correlation between transmission intensity and genetic diversity for both marker genes 
(Bendixen et al. 2001;Montoya et al. 2003;Peyerl-Hoffmann et al. 2001). 
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Our findings might have implications for genotyping samples from drug efficacy trials where 
recrudescence must be reliably distinguished from new infections and the probability of new 
infecting parasites having the same allele as the initial infecting parasite should be as low as 
possible. Our data suggest that for this purpose msp2 is the more suitable marker gene than 
msp1 in both study sites. Genotyping only msp1 would not provide adequate discriminatory 
power according to the standards suggested by Gatton and Cheng ( 2008) as the probability of 
being reinfected with the same genotype is 8.5%. In areas of lower transmission intensity, 
such as in PNG, genotyping only one marker gene (either msp1 or msp2) will not provide 
enough discriminatory power and two markers are necessary to improve discrimination 
power. In highly endemic areas like Tanzania, the resolution obtained with msp2 might be 
sufficient to discriminate all concurrent clones within an individual, as the probability of 
multiple parasites sharing the same allele is low. However, the high mean MOI in this area is 
likely to lower the discriminatory power. This effect of high MOI on the resolution of 
genotyping markers has so far been ignored in genotyping studies. It is of relevance in 
particular for genotyping of recrudescences in highly endemic areas, because high MOI 
increases the probability of concurrent parasite clones carrying the same genotype. We 
therefore made an attempt to estimate the true number of alleles present in a host, allowing for 
this probability. Details of the estimation approach are being published elsewhere (Ross et al. 
in preparation). Table 3 lists the probability of observed infections conditional on the true 
number of infections based on the PNG allelic frequencies. Adjustment for the probability of 
multiple infections sharing the same msp2 allele made little difference to the estimated MOI 
(estimated mean MOI was 1.84 in PNG, 3.99 in Tanzania compared to the unadjusted values 
of 1.84 in PNG and 3.72 in TZ, respectively). This reflects the low probability of being 
infected with two parasites sharing the same allele with such a high resolution typing system. 
  
In conclusion, our CE based genotyping, which provides highly accurate fragment sizing data 
is in line with previous findings on genetic diversity in different geographic locations. A 
higher mean MOI for both marker genes was found in an area of more intense malaria 
transmission. msp2 diversity was higher in the high transmission area, but msp1 only showed 
a minor increase in diversity. The between population variance in allele frequencies, as 
estimated by Wright’s F statistics, was found to be very low for both marker genes. This 
indicates that there was little genetic differentiation between the two sites of different 
endemicity and suggests that the observed patterns of allele frequencies are independent of 
transmission intensity. 
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Figure1: Allelic frequencies of msp1 and msp2 in samples from Papua New Guinea 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. White, grey and black areas indicate frequencies of K1, MAD20 and RO33 alleles, 
respectively. B. White and grey areas indicate Fc27 and 3D7 allele frequencies, respectively. 
 
 
 
Figure 2: Allelic frequencies of msp1 and msp2 in samples from Tanzania  
 
 
 
A. White, grey and black areas indicate frequencies of K1, MAD20 and RO33 alleles, 
respectively. B. White and grey areas indicate Fc27 and 3D7 allele frequencies, respectively. 
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Table1: Diversity of msp1 and msp2 in samples from Papua New Guinea and Tanzania 
 Papua New Guinea Tanzania 
 msp2 msp1 msp2 msp1 
Number of samples (n) 108 108 115 115 
Number of alleles 35 24 76 29 
Frequency of most common allele 15.08 % 16.28 % 11.21 %  20.57 % 
Number of clones 199 215 428 350 
Mean MOI* 1.84 1.99 3.72§ 3.04§ 
HE** 0.933 0.918 0.965 0.917 
P=∑pi2 0.07 0.084 0.036 0.085 
Combined probability*** 0.0058 0.003 
*
 MOI = mean multiplicity of infection  
**HE = expected heterozygosity. This is defined as the probability that two randomly chosen 
alleles are different in the population.  
***
 The combined probability that two independent clones share the same genotype for both 
marker genes was calculated by multiplying the probabilities P for both marker genes. 
§ Indicates significant difference between mean MOI of msp1 and msp2 (p<0.001) 
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Table 2: Number of different msp1 and msp2 alleles detected in samples from Papua New 
Guinea and Tanzania 
 
 
 
 
Table 3: Probability of each number of observed infections (rows), conditional on the true 
number of infections (columns). Results are shown for MOI≤5. 
 
 
 
 
 
 
 Papua New Guinea Tanzania 
Number of different msp1-K1 alleles 13 19 
Number of different msp1-MAD20 alleles 10 9 
Number of different msp1-RO33 alleles 1 1 
Number of different msp2-3D7 alleles 27 59 
Number of different msp2-Fc27 alleles 8 17 
 1 2 3 4 5 
      
1 1 0.068 0.007 0.0008 9.38E-05 
2  0.931 0.185 0.0358 0.007077 
3   0.808 0.3108 0.097212 
4    0.6526 0.404946 
5     0.490671 
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ABSTRACT 
 
Standard treatment for uncomplicated malaria in Papua New Guinea (PNG) is currently a 
combination of chloroquine or amodiaquine plus sulfadoxine-pyrimethamine. High levels of 
resistance against this treatment regimen give strong argument for the implementation of 
artemisinin based combination therapy (ACT) in the country as recommended by the WHO. 
A recent drug efficacy trial has reported the combination therapy Coartem® (artemether-
lumefantrine) to be highly effective against P. falciparum in children less than 5 years in 
PNG. In contrast, we have observed high levels of treatment failures in non-trial conditions in 
a longitudinal cohort study in the same age group in PNG. Recrudescences were confirmed by 
molecular genotyping of 3 different marker genes using a high resolution technique which 
provided optimal discrimination power between parasite clones. After excluding genetic host 
factors by genotyping potentially relevant cytochrome P450 loci, the high number of 
treatment failures in our study is best explained by poor adherence to complex dosing 
regimens in combination with insufficient fat supplementation, which are both crucial 
parameters for the outcome of Coartem® treatment. Opposed to the situation in classical drug 
trials with ideal treatment conditions, our field survey highlights potential problems with 
unsupervised usage of Coartem® in routine clinical practice.  
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INTRODUCTION 
 
With respect to increasing drug resistance, the World Health Organisation currently 
recommends a switch of first line treatment against uncomplicated malaria to artemisinin 
based combination therapies (ACT) for countries where conventional antimalarial treatments 
such as chloroquine (CQ), amodiaquine (AQ) or sulphadoxine-pyrimethamine (SP) have 
become ineffective [1].   
 
First line treatment for uncomplicated malaria in Papua New Guinea (PNG) has been 
chloroquine or amodiaquine plus sulphadoxine-pyrimethamine since the year 2000. However, 
the efficacy of this treatment regimen was found to be low only three years after its 
implementation [2], which gives a strong argument for the introduction of artemisinin-based 
combination therapies. A recent study conducted in Papua New Guinea [3] has tested the 
efficacy of different artemisinin-combination therapies in children <5 years with P. 
falciparum or P. vivax malaria. Artemether-lumefantrine was found to be the most effective 
combination therapy against P. falciparum with an adequate clinical and parasitological 
response of 97.3% at day 28 and 95.2% at day 42 after treatment.  
 
While the effectiveness of Coartem® (artemether-lumefantrine) under ideal trial conditions 
was very promising, the situation may look different in less controlled conditions in routine 
practice. It is likely that adherence to the recommended treatment is sub-optimal under non-
study conditions, because the rapid relief of symptoms might tempt patients to early interrupt 
treatment.  
 
We undertook a longitudinal study in PNG during which children between 1 and 5 years of 
age were followed up in 8-weekly intervals with the aim to investigate the infection dynamics 
of P. falciparum clones. All children presenting with a clinical malaria episode were treated 
with Coartem®. In our study, we observed an unexpected high number of P. falciparum 
recurrent infections which were confirmed by molecular genotyping of three different 
markers. Our observations are in contrast to recently published results of a drug efficacy trial 
in the study area [3]. We discuss our findings with respect to the forthcoming introduction of 
Coartem® as first line treatment in the country [4].  
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METHODS 
 
Study design and site. The study was carried out in an area near Maprik, East Sepik Province 
in Papua New Guinea which is endemic for malaria. There is little seasonal variation in 
temperature or rainfall and malaria transmission is perennial [5]. A detailed description of the 
study design is given elsewhere (Lin et al, in preparation). Briefly, 269 children 1-3 years of 
age at enrolment were followed-up in 8 weekly intervals from March 2006 until July 2007. At 
each visit the children were clinically assessed and a 250µl blood sample was collected from 
each participant by finger prick. In between these regular follow-up bleeds, each child was 
clinically examined every 2 weeks, and in case of malaria symptoms a 250µl blood sample 
was collected. Furthermore, a blood sample was collected at the local health centre whenever 
a study participant presented with malaria symptoms. During anytime of the study, 
symptomatic children that were confirmed to carry malaria parasites by rapid diagnostic test 
and/or microscopy were treated with a 6-dose regimen of Coartem® (Novartis Pharma, 
Switzerland) which was mainly administered unsupervised. Caretakers were advised to 
complete the full treatment regimen and to supplement the drugs with a fatty diet.  
Scientific approval and ethical clearance for the study was obtained from the Medical 
Research and Advisory Committee (MRAC) of the Ministry of Health in PNG and from the 
Ethikkommission beider Basel (EKBB) in Switzerland. Informed consent was sought from all 
parents or guardians prior to recruitment of each child.  
 
 
DNA isolation and msp2 genotyping. All finger prick blood samples were separated into 
plasma and cells. DNA was extracted from cell pellets using QIAamp® 96 DNA Blood Kit 
(Qiagen, Australia) according to the manufacturer’s instructions. All samples were genotyped 
for the highly polymorphic marker gene merozoite surface protein 2 (msp2) by capillary 
electrophoresis as previously described by Falk et al. [6] with some minor changes and 
adaptations of PCR conditions for highly purified DNA as described in Schoepflin et al (in 
preparation).  
 
 
Determination of treatment failures and msp1 genotyping. The current protocol of the 
WHO to assess drug efficacy recommends a follow-up of 28 days for most antimalarial drugs 
and an extended follow-up to 42 days for Coartem® [7]. In consideration of these guidelines, 
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the genotype dataset was screened for msp2 alleles that reappeared in the same patient within 
7-42 days after treatment with Coartem®. Since most of the study participants were treated 
several times throughout the course of the study, there were a total of 89 individuals that 
accounted for more than one entry in the database, but from different treatment time points 
during the survey. An outcome was defined as recrudescence if the first P. falciparum 
positive sample after treatment contained at least one msp2 allele that was identical to any of 
the alleles present in the treatment sample. An infection was defined as new infection when 
the first positive sample after treatment only contained new msp2 alleles. If the first positive 
sample contained both, alleles present in the treatment sample and new alleles, the outcome 
was considered recrudescent. As suggested by Mugittu et al. [8] we used a stepwise approach 
to discriminate recrudescent from new infections. All msp2 treatment failures were further 
genotyped for the polymorphic marker gene, merozoite surface protein 1 (msp1). For the 
amplification of the msp1 block 2 [9], a nested PCR approach followed by capillary gel 
electrophoresis was used (details see Schoepflin et al., 2009; in preparation). Classification as 
recrudescent or new infection was done in the same way as for msp2.  
 
 
Genotyping of microsatellite TA81. Samples identified as treatment failure by msp2 and 
msp1 and those samples for which msp1 PCR had failed were further genotyped for the 
polymorphic microsatellite TA81. Genotyping of microsatellite TA81 was only performed for 
follow-up samples collected within 28 days after treatment. Samples between day 28 and day 
42 were not further genotyped for TA81. Amplification of the TA81 locus was performed 
using primers and conditions previously described [10]. One of the amplification primers was 
5' end-labeled with Cy5. PCR products were mixed 3:1 (vol/vol) with denaturing loading dye 
buffer and analysed on a 6% denaturing polyacrylamide gel as previously described by DaRe 
et al. [11].  
 
 
Sequencing of cytochrome P450 and UDP-glucuronosyltransferase. Amplification of 
CYP3A4 was performed in a total volume of 50µl containing 5µl of 10xBufferB (0.8M Tris-
HCl, 0.2M (NH4)2SO4, 0.2% w/v Tween-20), 2mM MgCl2, 200µM dNTPs, 2.5U Taq DNA 
polymerase (FirePol, Solis BioDyne). PCR primers (forward: 
5’CTCACCTCTGTTCAGGGAAAC 3’; reverse: 5’ATGGCCAAGTCTGGGATGAG 3’) 
were used at a final concentration of 1µM each. 2.5µl of purified DNA was used as template 
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for this reaction. An initial denaturation step of 96°C for 3 min was followed by 40 
amplification cycles of 30 s at 96°C, 1 min at 64°C, 1 min at 72°C and a final extension for 10 
min at 72°C. PCR products were purified using NucleoSpin Extract II Kit (Clontech 
Laboratories, Inc.) and sequenced. Sequences were analysed using the ABI Prism 
AutoAssembler version 1.4.0 (Applied Biosystems) for assembly. Amplification and SNP-
genotyping of CYP2B6 516G>T and UGT2B7 802C>T was performed as previously 
described [12,13]. 
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RESULTS  
 
During the 16 months follow-up of our field survey a total of 793 Coartem® treatment 
regimens were administered to symptomatic children infected with P. falciparum, as 
diagnosed by msp2 PCR. 671 of these children were also positive by microscopy for P. 
falciparum and 188 carried mixed species infections at the time of treatment. Clinical and 
parasitological failure rates were determined in samples selected according to the inclusion 
criteria depicted in Figure 1. For determination of the parasitological treatment failure rate, 
only treated episodes occurring within 42 days prior to a regular follow-up visit were taken 
into account (Figure 1a). For clinical failure rate, two consecutive P. falciparum episodes of 
an individual were taken into account that both had occurred within an interval of 7 to 42 days 
(Figure 1b). The recurrent episode was detected either at regular follow up bleed or by active 
or passive case detection.  
 
Figure 2 summarizes genotyping results generated with three marker genes. Out of the 793 
Coartem® treated children, only 182 had a consecutive sample collected within the next 28 
days after treatment and 299 within the next 42 days. To estimate the parasitological 
treatment failure rate, all sample pairs were genotyped sequentially for 3 markers starting with 
the most polymorphic marker, msp2. For the remaining 494 Coartem® treated children, no 
consecutive blood sample was available within 42 days and these samples were excluded 
from further analysis. 
 
The PCR-corrected parasitological treatment failure rates were 36/182 (19.78 %) and 48/299 
(16.05 %) at day 28 and 42, respectively. Samples collected between day 28 and day 42 after 
treatment were only genotyped for msp2 and msp1 and final classification of infections 
occurring during this time period were therefore only based on these two marker genes. 
 
Out of the 793 P. falciparum episodes treated with Coartem®, 141 cases experiencing a 
further episode within 7-42 days after treatment. PCR-corrected clinical failure rates were 
26/793 (3.27 %) and 42/793 (5.3 %) at day 28 and 42 respectively.  
 
Cytochrome P450 genotypes. 64 different individuals representing persistent or new 
infections were genotyped for the cytochrome P450 3A4 392A>G and 2B6 516G>T and for 
the UDP-glucuronosyltransferase UGT2B7 802C>T which are all involved in the metabolism 
CHAPTER 4 
 76 
of artemisinin drugs and/or lumefantrine [14-17]. Sequencing of cytochrome P450 3A4 was 
successfully performed for 56/64 participants. Results from sequencing of cytochrome P450 
3A4 showed homozygote wild type carriers at position 392, i.e. adenosine, for all 56 
individuals. The P450 loci CYP2B6 516G>T and UGT2B7 802C>T were found to be 
polymorphic in the 64 individuals from our study population which was in agreement with 
previous results from the same population in PNG [12,13]. It has been proposed by these 
authors that the outcome of treatment with artemisinin drugs might be associated with a 
combined effect of polymorphisms in both CYP2B6 and UGT2B7 genes. In our study 
population, the combination of CYP2B6 516T and UGT2B7 802T was observed in individuals 
carrying new infections as well as in individuals showing treatment failures. There was a 
trend towards increased frequency of double mutants in individuals carrying recrudescent 
infections (30.3% of all CYP2B6-UGT2B7 double mutants were observed in individuals 
carrying new infections and 69.7% in treatment failures), however, the association between 
treatment outcome and the presence of double mutants in CYP2B6 and UGT2B7 was not 
statistically significant (p=0.79). 
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DISCUSSION 
 
A number of different drug trials were conducted worldwide to test the efficacy of artemether-
lumefantrine. This combination treatment has proven highly efficacious in studies conducted 
in Ghana [18], Tanzania [19,20], Thailand [21,22] or Papua New Guinea [3] with >97% PCR 
adjusted cure rates at day 28. In contrast, we observed an unexpected high number of 
recurrent infections after treatment with Coartem® in our longitudinal survey in children 
under 5 years of age in Papua New Guinea. Treatment failures were confirmed by molecular 
typing of three different marker genes using a high resolution technique with optimal 
discrimination power between genotypes. Using 3 different marker genes for discrimination 
of recrudescent from new infections provides confident identification of treatment failures. In 
the drug trial by Karunajeewa et al. [3] only microscopy positive recurrent infections were 
genotyped. In our analysis, all samples were genotyped irrespective of microscopy results. 
Since sensitivity of PCR is considerably higher than that of microscopy, we most likely have 
detected recrudescences of low parasite density that would have remained undetected by 
microscopy. This might have contributed to the higher treatment failure rate in our study.  
 
Our study was not designed as a classical drug efficacy trial, but as a cohort study with 
longitudinal follow-up in 8-weekly intervals. This study design does not allow estimating in a 
standardized way the true rate of parasitological treatment failures, because recrudescent 
infections were only detected when the treated episode occurred within 28 or 42 days prior to 
a regular follow-up visit. If the interval between the episode and the next regular follow up 
bleed was longer than 42 days, any recrudescent or newly occurring parasitaemia remained 
undetected. Thus, with our study design we certainly underestimated the number of both, 
recrudescences and new infections. However, the specific advantage of our study consists in 
the fact that treatment success was viewed outside a clinical trial setting with outcomes 
reflecting the local situation in village health care. Our finding of a substantial number of 
recrudescences in non-trial conditions highlights potential problems of unsupervised 
Coartem® usage.  
 
In principle, several factors could have reduced the effectiveness of Coartem® treatment in 
our study: (i) reduced sensitivity of parasites to Coartem®; (ii) host factors accounting for 
differences in metabolism of the drug; (iii) inadequate adherence to treatment regimen; (iiii) 
suboptimal absorption of drugs.  
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A reduced sensitivity to artemether-lumefantrine has been associated with an increased copy 
number of pfmdr1 in vitro and in vivo [22]. Similar findings of a reduced sensitivity to 
lumefantrine in vitro were described by Lim et al. [23], however, in that study the correlation 
could not be confirmed in vivo. Recently, it has been shown that pfmdr1 gene amplifications 
were absent from different study sites in PNG, including an area adjacent to our study site 
[24]. These results, together with the fact that an efficacy trial [3] had confirmed Coartem® to 
be highly effective in our study area indicate that reasons other than reduced drug sensitivity 
due to an increase in pfmdr1 copy numbers are more likely to account for the high frequency 
of recrudescent infections.  
 
Artemisinin derivatives are mainly metabolized by the human cytochrome P450 3A4 [15] and 
2B6 [17] and also by the metabolic enzyme UDP-glucuronosyltransferase UGT2B7 [16]. The 
lumefantrine component of Coartem® is also metabolised by CYP3A4 [14]. So far functional 
significance of polymorphisms in CYP2B6 and UGT2B7 on the treatment outcome of 
artemisinin drugs is lacking. However, previous in vitro studies have shown that these 
polymorphisms caused significant reduction in enzyme activity or expression [12,13] which 
generally elevated the plasma drug concentration of a antiretroviral drugs [12]. It is likely that 
these polymorphisms act in a similar way on artemisinin plasma levels, and it has been 
proposed by Mehlotra and others [12,13], that the large inter-individual variability in the 
pharmacokinetics of artemisinin drugs which has frequently been observed might partly be a 
result of a joint contribution of both polymorphisms in CYP2B6 and UGT2B7. In order to 
exclude the possibility that host genetic factors account for the frequent treatment failures in 
our study population, polymorphisms in the human cytochrome 3A4, 2B6 and in UGT2B7 
were investigated. For the CYP2B6 and UGT2B7 we only focused on the two polymorphisms 
CYP2B6 516G>T and UGT2B7 802C>T which have been observed at high frequency in a 
previous study in PNG [12,13]. We found mutant alleles in both, patients carrying new 
infections as well as in recrudescent infections, but treatment outcome and the presence of 
double mutants were not significantly associated. Thus the double mutant CYP2B6/UGT2B7 
seems not to influence the outcome of Coartem® treatment in this population. However, the 
trend towards increased proportion of double mutants in patients with treatment failures 
suggests that the correlation between treatment outcome and presence of double mutant 
should be further investigated in a bigger study population under standard drug trial 
conditions. The mutant allele CYP3A4 392A>G has previously been associated with a 
significant decrease in CYP3A4 activity [25] and therefore leads to an increased exposure to 
CHAPTER 4 
 79 
lumefantrine. Our sequencing results did not reveal any polymorphisms at position 392. 
Homozygous carriers of the wild type SNP were found in individuals harbouring recurrent or 
new infections. These results indicate that differences in metabolism of lumefantrine due to 
mutations in CYP3A4 do not seem to account for the frequent treatment failures observed. 
 
In most drug efficacy studies, treatment regimens are administered under supervision of a 
team nurse and therefore optimal compliance is mostly guaranteed or at least information on 
the adherence to the recommended treatment intervals or early interruption of treatment are 
available and can be accounted for in the analysis. In our study, treatment was mostly 
administered unsupervised. Parents were encouraged to complete all treatment doses, but in 
fact, no information is available from our study participants whether or not the complete 
treatment regimen was taken. Coartem® rapidly alleviates malaria symptoms, which might 
frequently tempt patients to stop treatment earlier and keep the remaining tablets for a later 
malaria attack. Incomplete adherence to the full 6-dose regimen might have contributed to the 
observed frequency of treatment failures. 
 
After initial reduction of the parasite biomass by the fast acting artemether, clearance of the 
residual parasites greatly depends on the longer lasting partner drug lumefantrine. Previous 
studies have shown that the plasma level of lumefantrine is a critical factor for treatment 
success [22,26]. Food has a significant effect on the bioavailability of both components of the 
drug with an increased absorption when supplemented with fatty food [27]. An increase in 
treatment success by 15% was observed in a study in Thailand when a fatty diet was co-
administered with Coartem® [28]. In the present study, parents or guardians of the study 
participants were advised to administer treatment with a fatty diet, however, no information 
are available to what extent these recommendations were followed. Inadequate plasma 
concentrations of lumefantrine might therefore have contributed to the high rate of treatment 
failures.  
 
The high frequency of parasitological and clinical treatment failures in our study are contrary 
to findings from a recent drug efficacy trial which was conducted in an area adjacent to our 
study site. In this previous study Coartem® was reported to be highly effective in clearing P. 
falciparum in children under 5 years of age [3]. An important difference between the two 
studies was that in the drug efficacy trial at least half of the doses were dispensed under 
supervision and supplemented with milk. This implies that incomplete adherence to the 
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treatment regimen in combination with a lack of fatty diet might have contributed to the 
observed differences in treatment outcome. Furthermore, in our study Coartem® was also 
given to P. falciparum infected children who presented with anaemia (Hb<7.5), but did not 
show any other sign of symptoms. It is likely that these children were even less adherent to 
treatment, because they were without noticeable signs of disease.  
 
Rather low levels of drug efficacy had also been reported from two studies in Ghana [29,30], 
where PCR corrected cure rates at day 28 were only 86.2% and 88.3%, respectively. In one of 
these studies only the first dose was given under supervision, whereas in the other study the 
administration of all 6 tablets was supervised. In both studies, no fatty diet was provided by 
the study team, but caretakers were encouraged to give fatty food at the time of drug 
administration. It was not checked by the study team whether these recommendations were 
followed. In a study in Uganda, no difference in treatment efficacy was observed between 
supervised and unsupervised administration of Coartem® [31]. In the latter study, detailed 
explanations on intake of tablets and treatment schedule were provided to the patients. Such 
information may have resulted in adequate adherence.  
 
In summary, our observations highlight the importance of strict adherence to the complex 
dosing regimens of Coartem® and the need to supplement the treatment with a fatty diet. The 
study by Kuranajeewa et al. [3] had shown that under optimal treatment conditions Coartem® 
was highly effective in Papua New Guinea, whereas our results indicate that these high 
success rates might be difficult to achieve under routine clinical practice. Thus, it is of great 
importance that the introduction of Coartem® as first line treatment in PNG is accompanied by 
provision of training and education for health workers to guarantee accurate treatment and 
compliance to the recommended guidelines. As pointed out by Piola et al. [31] a great effort 
has to be made to convince patients and caretakers to complete the full 6-dose regimen 
despite the fast relief of symptoms. 
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Figure 2. Summary of final treatment outcome based on msp2, msp1 and TA81 genotyping 
FUB= follow-up bleed;* Genotyping of the microsatellite TA81 was only performed for 
infections occurring within 28 days after Coartem® treatment. Samples collected between day 
28 and day 42 after treatment were genotyped only for msp2 and msp1.  
 
 
All episodes with subsequent FUB within 28 or 42 days 
n28 days = 182 
n42 days= 299  
FUB negative by msp2  
n28 days = 98 
  n42 days = 164  
recrudescent infections 
n28 days = 36 
n42 days = 48  
 
FUB positive by msp2, msp1, TA81* 
(stepwise genotyping)  
new infections  
n28 days = 48 
n42 days = 87  
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CHAPTER 5: Estimates of detectability of P. falciparum and force of 
infection based on molecular data 
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ABSTRACT  
 
Background: In areas endemic for malaria, most people are simultaneously infected by 
different P. falciparum clones. Detection of all clones concurrently present in a host is 
complicated by sequestration of parasites during part of their life cycle, or by densities 
fluctuating around the detection limit of molecular typing. This shortfall has implications for 
basic measures of epidemiology or for outcome measurements of clinical trials. To 
quantifying the proportion of undetected parasite clones, we estimated detectability by 
repeated sampling and determined its effect on multiplicity of infection (MOI) and force of 
infection (FOI)  
Methods: A longitudinal field survey was conducted in 1-4.5 years old children from Papua 
New Guinea over 16 months with follow-up visits in 2-monthly intervals. At each visit two 
blood samples were collected 24 hours apart from each child. Samples were genotyped for the 
polymorphic marker gene msp2. Detectability was estimated from the presence of genotypes 
at either both days or only one day. MOI and FOI were determined for single or repeated 
blood sampling.  
Findings and Conclusion: FOI was defined as the number of parasite clones acquired per 
time. Different approaches to measure FOI were tested. When new clones infected a parasite-
free host after treatment, FOI was found to be substantially higher compared to estimates of 
FOI in absence of treatment. Without interference of antimalarials, competition between 
newly acquired and already persisting infections could lead to the low FOI observed. 
Detectability was 0.79 in our data set and we found that conducting 24h bleeds had only a 
marginal impact on measures of MOI and FOI. This led us to conclude that the additional 
efforts and costs of such a study design do not justify short term sampling in future studies of 
this age group.  
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INTRODUCTION 
 
Development of PCR based genotyping techniques has greatly increased knowledge about 
infection dynamics of Plasmodium falciparum. Studies on multiplicity of infections, 
incidence and clearance rates or duration of infections became possible by genotyping 
longitudinal samples. Molecular genotyping has also been used to improve classification of 
treatment outcome in drug trials. Irrespective of the application of these techniques, 
researchers always face the problem of imperfect detectability of parasites due to the fact that 
P. falciparum is periodically absent from the peripheral blood. The parasite sequesters in 
blood vessels for part of its 48 hour life cycle. In addition, detectability is influenced by the 
detection limit of the applied technique. Highly complex dynamics of P. falciparum were 
previously observed in children followed-up on a daily basis and the composition of 
infections was found to be unstable over time and even changing from one day to another [1]. 
This implies that a single blood sample only partly represents the true parasite population 
present in a host. Several publications have addressed the issue of imperfect detectability and 
described mathematical models to estimate infection dynamics of P. falciparum under 
conditions of imperfect detection of parasites [2-4]. The model by Sama et al. [2] was applied 
for a longitudinal field study in Ghana, where consecutive blood samples were collected from 
each participant in 2 monthly intervals. From this dataset, the detectability by PCR-RFLP was 
estimated as approximately 0.45, meaning that on average only 45% of the parasites present 
in a host are actually detected. Bretscher et al. (in preparation) have outlined a method to 
estimate the detectability of infection for P. falciparum based on pairs of samples collected in 
such small time intervals that re-infection with a new parasite clone can be excluded. 
Detectability for sample pairs that were collected between 1 and 7 days apart were estimated 
to take values between 0.45 and 0.63. We have now applied the same method to a large set of 
paired samples that were collected 24 hours apart.  
 
Imperfect detectability might also have important implications for estimating the incidence of 
infection. This was observed in a treatment to re-infection study in Papua New Guinea [5], 
where two weeks after antimalarial treatment a remarkable proportion of microscopy-negative 
children were positive for any Plasmodium spp. by PCR based detection. Compared to the 
standard method of detecting parasites by microscopy, PCR based detection of parasites has 
the advantage of being more sensitive and therefore has the capacity of detecting infections at 
an earlier time point when parasite density is still under the detection limit of microscopy. 
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More precise measures for calculating incidence rates can be obtained by genotyping 
techniques that distinguish co-infecting parasite clones within one host. However, despite 
improved detection through molecular techniques parasite clones remain undetected due to 
sequestration or densities fluctuating around the detection limit of PCR. Thus, imperfect 
detectability of P. falciparum infections may lead to underestimates of the force of infection 
(FOI).  
 
In the study presented here, a large number of samples collected 24 hours apart from a cohort 
of Papua New Guinean children were genotyped to calculate the detectability of infection and 
to investigate the benefit of collecting 24h bleeds on basic measures of epidemiology such as 
the multiplicity of infection or the force of infection. 
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METHODS 
 
Field survey and patients 
This study was conducted in a rural area near Maprik, East Sepik Province, Papua New 
Guinea. A detailed description of the study is given elsewhere (Lin et al., in preparation). 
Briefly, 269 study participants were enrolled at an age of one to three years starting in March 
2006. Since during the first round of sampling the expected number of participants could not 
be reached, late enrolments were conducted for the remaining children in the consecutive 
sampling rounds. Regular follow-up visits were conducted in 8-weekly intervals over a period 
of 16 months until July 2007. Except for the first and last round of sample collection, two 
consecutive blood samples were collected by finger prick at intervals of 24 hours for each 
study participant at each follow-up visit (in the following termed: 24h bleed). Each individual 
contributed up to 16 samples, 14 of which were paired samples with 24 hour intervals. Active 
and passive case detection was performed between the regular 8-weekly follow-up visits and 
a blood sample was collected from all participants with suspected malaria infection and a 
rapid diagnostic test (RDT) was performed. Antimalarial treatment with Coartem® (Novartis, 
Switzerland) was administered upon a positive RDT or if haemoglobin levels were <7.5 g/dl. 
Informed consent was sought from all parents or guardians prior to recruitment of each child. 
Scientific approval and ethical clearance for the study was obtained from the Medical 
Research and Advisory Committee (MRAC) of the Ministry of Health in PNG and from the 
Ethikkommission beider Basel in Switzerland.  
 
 
Laboratory procedures 
All finger prick blood samples were separated into plasma and cells. DNA was extracted from 
cell pellets using QIAamp® 96 DNA Blood Kit (Qiagen, Australia) according to the 
manufacturer’s instructions. All samples were genotyped for the polymorphic marker gene 
merozoite surface protein 2 (msp2) by use of capillary electrophoresis for fragment sizing as 
previously described by Falk et al. [6] with some minor changes and adaptations of PCR 
conditions for highly purified DNA as described by Schoepflin et al. (manuscript in 
preparation).  
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Data analysis 
Analysis of 24h interval bleeds. For data analysis pairs of samples that were collected 24 
hours apart were considered from each individual. Sample pairs were excluded from the 
analysis if antimalarial treatment was given on the first day. For each genotype, each sample 
pair was classified by positivity on each of the two days, leading to three categories for each 
genotype, negatives (where the genotype was not observed, with frequency n0 ), singles 
(where it was observed in one sample, n1) and double positives (n2). An estimate, q% , of the 
detectability, q, is to equate it to the proportion of positive observations among all 
observations where the genotype is present, which gives, allowing for the negatives, the 
following:  
2
1 2
2
2
nq
n n
=
+
%
 (Bretscher et al., in preparation). An approximate confidence interval was 
calculated as follows: CI [q± 1.96 se(q)], where the standard error is :  
1 2 1 2
2
1 2
2 ( )( ) ( 2 )
n n n n
se q
n n
+
=
+
. 
 
The age on day 1 of each 24h bleed was calculated for each individual and the detectability 
was calculated for different age groups. Comparison of proportions between day 1 and day 2 
samples was done by McNemar’s exact test for paired data. 
 
 
Force of infection. For estimating the force of infection (FOI) the time period between an 
antimalarial treatment and first re-infections after treatment was calculated. Since the study 
design only allowed for sample collection at predefined dates (8-weekly intervals) or when a 
participant had malaria symptoms, this time period can only be determined approximately. 
Recrudescent infections as determined by msp2 genotyping that emerged within 15 days after 
Coartem® treatment were excluded from the analysis. This corresponds to approximately 3 
times the elimination half life of lumefantrine. New infections occurring within this time 
period were also excluded. The age was calculated for each participant at the time of 
treatment and 3 age categories were made (1-2 years; 2-3 years; >3 years). Kaplan-Meier 
failure estimates were calculated and plotted for different age groups, and a log-rank test for 
equality of survivor functions across groups was performed at a 5% significance level.  
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As a second approach to estimate FOI we observed the number of newly acquired P. 
falciparum clones occurring between any two consecutive Coartem® treatments. Poisson 
regression was used to examine effects of different covariates on the number of acquired 
clones per time and the FOI was modelled on ln(
t
n ) as a linear function of the covariates, 
where n is the number of newly acquired infections, and t is the length of the interval between 
treatments. Random effect models were examined to correct for potential clustering. 
Furthermore, FOI in absence of antimalarial treatment was estimated. For this analysis, an 
interval was defined by two blood slides from the same individual at successive 8-weekly 
follow-up bleeds (FUB). The number of newly acquired clones was observed for each 
interval. Intervals were excluded for this analysis if treatment was given at start or during the 
interval. Intake of antimalarials within 15 days prior to start of the interval was also an 
exclusion criterion for this analysis. A total of 605 intervals of 8 weeks were eligible for this 
analysis. 3 samples were genotyped per interval. The samples at start and end of an interval 
were monitored, plus the last sample collected prior to the interval. The latter was required to 
classify a parasite clone as new or persistent infection. The genotype sample triplets were 
recorded as 3 digit codes, 001, 011, 010, 110, 101, 111, where the first position indicated the 
presence or absence of a specific genotype in the sample prior to the interval, and the second 
and third position represented this genotype in the first and last sample of the interval:  
111, denoted the presence of an allele in all three samples, which was indicative for 
persistence; 011, denoted the presence of a genotype already at the beginning of an interval 
and was therefore classified as persistent infection; 001, stands for a new acquisition of a 
genotype during the interval monitored. 010, denoted the loss of a genotype during the 
interval monitored; 101, denoted the detection of an allele prior to interval start and at the end 
of the interval, and failure to observe an allele at the start of the interval, which was indicative 
for imperfect detection at interval start. This sequence was considered a persistent infection.  
With this strategy, the number of newly acquired clones during 605 8-weekly intervals was 
identified. FOI was estimated in different age groups by fitting a Poisson regression model, as 
in the previous approach. 
 
All statistical analysis was performed using STATA® 9.1 statistical analysis software (Stata 
Corporation, College Station, TX). Models were compared using AIC (Akaike's Information 
Criterion) as measure of goodness of fit. Lower values of AIC indicate a better fit to the data. 
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RESULTS 
 
Effect of repeated sampling 
For the analysis of paired samples collected in 24h intervals a total of 1016 pairs were 
eligible. Of these, 311 pairs were positive at least on one day. Table 1 summarizes the msp2 
PCR results on day 1 and day 2. Overall the prevalence of P. falciparum infection did not 
differ significantly between the two days (27.85% on day 1 vs. 28.54% on day 2; Mc Nemars 
test: χ2=1.0, p=0.39), but a slight increase in prevalence up to 30.61% was observed, when 
results from both days were combined.  
 
When the presence of msp2 alleles was compared between samples from 2 consecutive days, 
considerable variation in the presence of alleles was observed: 35.33% of all genotypes were 
only observed on either day. Table 2 summarizes the presence of genotypes in all paired 
samples collected in 24h intervals. Combining the genotyping results from both days led to a 
small increase in mean MOI to 1.68 compared to mean MOI of 1.52 on day 1 and 1.47 on day 
2 determined for sampling only once (ttest for paired data: t=-8.4990, p<0.001). 
 
 
Detectability 
We estimated a very high detectability of 0.79 for all pairs of samples collected 24 hours 
apart. Table 3 lists the detectability calculated for different age groups. No significant 
difference was observed between the 3 groups.  
 
 
Force of infection after treatment with Coartem® 
The time to occurrence of the first new infection after antimalarial treatment is a measure of 
FOI. In Kaplan-Meier survival analysis, increasing FOI is leading to steeper slopes of the 
failure curves. The log-rank test for comparison of time to first infection between children of 
different age groups showed a significant difference between survivor functions (p<0.001). 
The Kaplan-Meier failure estimates for the three different age groups show a faster re-
infection of children with increasing age (Figure 1). The median number of days to first 
infection was 49 days (inter quartile range (IQR) [31, 69]. 
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In order to obtain a numerical value for FOI from our data, we assumed that times until re-
infection follow an exponential distribution with rate λ, corresponding to FOI, with λ
∑
=
t
r
, 
where ∑t is the total time at risk in the population and r is the total number of new infections 
observed. The assumption of an exponential distribution of times to re-infection was verified 
by comparison of the cumulative hazard obtained from our data with the theoretical values. 
The two curves showed a good fit (data not shown) indicating that our data can justifiably be 
assumed to follow an exponential distribution. The overall force of infection (λ) for the time 
to first infection was estimated 3.29/child/year. 
 
A further estimate for FOI was calculated by measuring the number of newly acquired P. 
falciparum clones between any two consecutive treatments with Coartem®. A Poisson 
regression model was used to determine the relation between age and the number of clones 
acquired per time. Heterogeneity in FOI among villages was accounted for by random effect. 
An increased FOI was observed with increasing age of the children (Figure 2). This analysis 
was also performed for genotypes observed at the first day 1 of any 24 hour sample pair. As 
expected, the number of clones detected was lower and this led to a lower estimate of FOI. 
The average FOI was 4.85/child/year when genotypes from both paired samples taken 24 
hours apart were considered and 4.49/child/year when only genotypes present on the first day 
were taken into account. The trend of an increased FOI with increasing age was also seen 
when only the first sample of each 24h sample pair was used to estimate FOI (Figure 2).  
 
 
Force of infection in absence of antimalarial treatment 
To estimate FOI in absence of treatment a Poisson regression model was fitted to determine 
the relationship between age and the number of newly acquired clones per 8-weekly interval. 
Similar to the previous analysis, the model was adjusted for the village of residence. The age 
relationship was similar to the previous model and also showed an increased FOI with 
increasing age (Figure 2). FOI after antimalarial treatment was on average 2.91/child/year, 
which was overall approximately 1.7 times lower compared to the FOI estimated after 
antimalarial treatment. 
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DISCUSSION 
 
Imperfect detectability of P. falciparum in blood samples occurs when parasites sequester in 
the deep blood vessels for part of their life cycle or when parasite densities fluctuate around 
the detection limit of PCR. Therefore a single blood sample might not be representative for 
the entire parasite population in a host. Imperfect detection is a major constraint for molecular 
epidemiology of P. falciparum. Parameters such as prevalence by PCR, MOI or duration of 
infection are compromised.  
 
The focus of this work was to investigate changes in the genotypic profile of parasite 
populations within a host over a period of 24 hours. We aimed at quantifying for our study 
site the daily fluctuations reported from studies made in Africa, that had shown considerable 
fluctuations in the presence of alleles from one day to another [1,7]. Our analysis of PCR 
positivity in samples collected 24 hours apart revealed limited day to day fluctuations and 
showed that short term sample collection has only a marginal impact on the outcome of the 
prevalence when results from 24h bleeds were combined. Combining the msp2 genotyping 
results from both days resulted only in a small increase in the mean MOI compared to results 
obtained from a single sample (1.52 vs. 1.68). This is reflected in the very high detectability 
of 79% estimated in our analysis. Children <5 years most likely have not yet developed a 
strong immunity and therefore carry high parasite densities (mean parasite density: 9503.23, 
95% CI [5438.71, 13567.75]), which leads to a better chance to detect most of the parasites 
present by PCR. In comparison, a previous study conducted in a highly endemic area in 
Ghana had estimated an overall detectability of only 35% [6] and reported an age-dependency 
of detectability [3]. However, this low value for detectability reported form Ghana was 
derived from individuals of all age groups. Furthermore, a less sensitive genotyping 
technique, PCR-RFLP, was used and detectability was estimated by a different approach 
using samples collected in 2 monthly intervals. Despite these obvious differences, our 
estimate of detectability of 79% in 1-4.5 years old children compares well with the estimate of 
about 60% in children of the same age from Ghana [3]. The overall very low detectability of 
35% in all ages in the Ghana study is due to the extremely low detectability of about 10% in 
adults [3]. Such reduced detectability in older individuals from endemic areas is thought to 
depend on their low parasite densities controlled by acquired immunity. The strong age trend 
seen in the Ghana study was not found in our study. The reason for this is likely the narrow 
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age range in our study and the focus on children harbouring high parasite densities due to not 
yet or only partly developed immunity.  
The differences in endemicity between our study site and the survey area in Ghana might also 
have influenced the differences in detectability. In high transmission areas like Ghana, where 
individuals frequently harbour high MOI, the chance to amplify only the dominant clone in a 
PCR reaction and to miss minority clones due to template competition is higher than in areas, 
where infections are less complex.  
 
We investigated the impact of repeated sampling on estimates of FOI. When the number of 
newly acquired clones between any two consecutive Coartem® treatments was used to 
estimate FOI, we observed an increasing number of clone acquisition with increasing age. 
When only the first sample of each 24h bleed was used for the same analysis, the total number 
of clones observed was lower leading to an overall lower estimate of FOI. It is note worthy 
that the observed trend of an increased FOI with increasing age was not altered when taking 
into account either a single sample or both paired samples collected 24 hours apart. Short term 
consecutive blood sampling therefore provided an improved picture of the parasite population 
present in a host and led to more precise epidemiological measures, such as prevalence of P. 
falciparum, FOI, or MOI.  
 
The major disadvantages of sampling on consecutive days were a considerable increase in 
efforts in the field and laboratory, added costs, and additional discomfort for study 
participants. As children were visited in their villages, a duplication of samples collected and 
processed inflicted a substantially increased workload on the field team. The limited benefit 
for more precise estimates of malariological parameters does not justify routine 24h bleeds for 
future studies. The considerable logistical efforts required for this sampling scheme seems 
prohibitive and not justified in this age group. However, in older children and adults such 
increased efforts might well be justifiable or even required, because in endemic areas older 
individuals often carry lower density infections as a result of acquired immunity. 
Accordingly, detection in these age groups will be impaired. Our conclusion on a single 
sample being sufficient might therefore not apply to studies conducted in older individuals.  
 
In a second approach, we used the time between antimalarial treatment and the appearance of 
the first new P. falciparum clone to measure FOI. Similar to the estimates of FOI described 
above, the age distribution showed that children older than 3 years of age were re-infected 
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faster and that there was a significant trend towards shorter time to re-infection with 
increasing age. Incidence rates of P. falciparum estimated by microscopy in an endemic area 
in Nigeria, Garki, increased up to 5-8 years and decreased thereafter [8]. A study conducted in 
a highly endemic area in Ghana using a more sensitive technique to detect new infections 
reported an increase in the number of newly acquired infections up to the age of 5-9 [3,6]. 
Even though we looked at a very narrow age range, our results confirmed these previous 
findings.  
 
In an alternative approach FOI was estimated in absence of antimalarial treatment by 
measuring the number of newly acquired clones between any two consecutive follow-up 
visits. The age relationship of FOI was similar to the first approach in showing an increased 
FOI in older children, but estimates were overall approximately 1.7 times lower. The 
advantage of this analysis is that it provides an estimate of FOI under natural conditions. The 
natural FOI is reflected more closely in absence of antimalarial treatment, where newly 
acquired parasite clones have to establish themselves in an already infected host and compete 
against persisting infections. Several studies indicated that established infections do protect 
against superinfections with new P. falciparum clones [9-11]. Artificial infections of mice 
have also shown that already present parasite clones have a competitive advantage over newly 
incoming clones [12]. The lower number of clone acquisition per time in absence of 
antimalarial treatment might therefore be a result of competitive interactions between clones 
which might affect the ability of newly incoming parasites to establish in the host. Therefore, 
the estimates of FOI, obtained from our alternative approach that does not study clone 
acquisition after treatment, most likely represent more precise values. The major reason for 
the observed discrepancy in FOI determined either after treatment or in absence of treatment 
is likely due to overestimation of FOI between two treatments. Overestimates are caused by 
the fact that each interval surveyed was terminated by a morbid episode which in turn is 
associated with clone acquisition in most of our observations ([13,14] Schoepflin et al., in 
preparation). Thus a selection bias towards higher clone acquisition was probably introduced 
in this approach. 
 
Our 3 approaches to estimate FOI from molecular data resulted in different values for FOI. 
The question arises which approach is the most appropriate? Molecular genotyping allows 
distinguishing persistent from newly acquired parasite clones and therefore provides the 
possibility to investigate the clone acquisition in absence of antimalarial treatment. Despite 
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the fact that all 3 approaches showed a consistent increase of FOI by age, the measure of FOI 
in absence of treatment seemed to provide the best estimate of the natural FOI, because it took 
into account competition between parasite clones, when newly acquired parasites have to 
establish themselves in an already parasitized host. In contrast, measures of FOI after 
treatment did not account for competition between parasite clones and therefore likely 
represented an overestimation of FOI.  
 
Generally, all estimates of FOI presented here, irrespective of the approach applied, were 
probably underestimates, since samples were only collected in 2-monthly intervals. Values of 
FOI were further hindered by imperfect detectability of parasite clones. However, since these 
shortfalls apply to all approaches to measure FOI and to all age groups the overall trend of an 
increasing FOI with increasing age should not have been influenced. 
 
Our observation of numbers of new infections increasing with age suggests that risk factors 
are acquired with increasing age. These factors must be opposing the benefits of acquired 
immunity which in turn reduces the risk of acquiring new infections. A number of studies 
reported a positive relationship between the biting rate of mosquito vectors and the biomass of 
the human host, i.e. with increasing weight or body surface of the host an increased number of 
mosquito bites was observed [15,16]. Therefore, one would expect an increase in the number 
of new infections with increasing age and therefore biomass. Since the detectability was 
identical between all age groups in our study differential detectability cannot explain the 
observed difference. Therefore, we propose that a possible explanation for the observed trend 
in our dataset could be an increased risk of getting bitten by mosquitoes with increasing 
biomass (Figure 3). Other factors such as changes in behaviour as children grow older are also 
likely to have an impact on the observed increase in acquisition of clones.  
 
The 2 major outcomes of this study were on the one hand the high detectability of parasite 
clones observed in children <5 years from PNG. This resulted in a marginal improvement of 
measures of MOI and FOI by short term sampling in intervals of 24 hours and led us to the 
conclusion not to recommend for this age group consecutive bleeds after 24 hours, because of 
immense additional efforts, costs, and discomforts to the study participants. The second main 
finding was that genotyping in longitudinal samples facilitates determination of the natural 
FOI since it allows measuring the number of clones acquired in absence of treatment. This 
avoids a bias through colonization of an empty niche which is introduced by treatment.  
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Table 1: Positivity by PCR in 2 consecutive bleeds 24 hours apart 
  
frequency in relation to number of  
pairs with at least one positive PCR 
msp2 PCR result number of pairs (n=311) 
1st sample positive 21 6.75% 
2nd sample positive 28 9.00% 
Both samples positive 262 84.24% 
% discordant1  15.76% 
1Proportion of sample pairs carrying a malarial infection only diagnosed on one day 
 
 
 
Table 2: Presence of msp2 genotypes in 2 consecutive bleeds 24 hours apart 
  
frequency in relation to number of 
genotype pairs with at least one  
genotype present on either day 
msp2 genotyping result number of pairs (n=518) 
allele present only in 1st sample 93 17.95% 
allele present only in 2nd sample 90 17.37% 
allele present in both samples 335 64.67% 
% discordant1  35.33% 
1Proportion of genotype pairs for which an msp2 allele was only diagnosed on one day 
 
 
 
Table 3: Detectability of parasite clones in different age groups 
Age group Detectability CI 
1-2 years 0.8 [0.71 – 0.88] 
2-3 years 0.81 [0.77 – 0.85] 
>3 years 0.75 [0.70 – 0.81] 
 
CHAPTER 5 
 104 
 
 
Figure1: Kaplan Meier failure estimates, showing the time to first infection after antimalarial 
treatment for different age groups. 
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Figure 2: Force of infection in relation to age. The number of clones acquired per time 
interval was used to fit a Poisson regression model to describe the relationship between the 
force of infection (λ) and age. The FOI is depicted as the number of new infections acquired 
per child per year.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Relationship between age (in months) and weight (in kg) of all study participants.  
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CHAPTER 6: Risk factors for P. falciparum episodes in children from 
Papua New Guinea 
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ABSTRACT 
 
Background: Previous studies have suggested that high multiplicity Plasmodium falciparum 
infections may protect against subsequent malaria morbidity. Methods: In a longitudinal 
study of 269 children between 1 and 4.5 years of age from Papua New Guinea (PNG) we 
analysed parasitological risk factors for P. falciparum morbidity. Repeated blood sampling 
was conducted in regular 2-monthly intervals and at any time point of presumptive malaria 
symptoms. The diversity of P. falciparum infections was assessed by msp2 genotyping. 
Results: There was a very high turnover of parasites associated with high morbidity rates. A 
decreased proportion of episodes in patients concurrently infected with different Plasmodium 
species and a lower P. falciparum density in these samples were indicative for species 
interactions. In children >3 years, a concurrent infection with a heterologous species was 
associated with higher multiplicity of infection (MOI). In a prospective analysis of 
parasitological risk factors for episodes a higher MOI was found to protect children > 3 years 
old against subsequent clinical attacks, which highlighted interdependence of co-infecting 
parasite clones. Discussion: Our study adds to the evidence that ongoing asymptomatic 
infections appear to offer cross-protection against invading clones. The association of high P. 
falciparum MOI with the presence of other Plasmodium species might be due to mixed 
species infections being treated less often because of lower parasite densities, thus allowing 
accumulation of multiple parasite clones over an extended period of time. These findings 
might have implications for the treatment policy of asymptomatic infections and for 
development and introduction of malaria control interventions.  
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INTRODUCTION 
 
In individuals from malaria endemic countries, protective immunity against malaria is 
acquired after repeated P. falciparum infections. Such slow and incomplete acquisition of 
protection is thought to depend on exposure to antigenically distinct parasites characterized by 
extensive antigenic diversity and antigenic variation [1]. The peak incidence of malaria 
morbidity in endemic areas varies with the level of endemicity; in Papua New Guinea (PNG) 
it is found in children under 5 years [2,3]. As a result of acquired immunity, older children 
and semi-immune adults in endemic countries usually have lower prevalence of infection, 
carry chronic, low density infections, and have developed an almost complete protection 
against severe illness (for example [2,4-6]). Protection against disease and protection against 
parasitization might be governed by quite distinct immune mechanisms [5,7]. 
 
Multiplicity of infection (MOI) is the number of parasite clones concurrently infecting one 
carrier. In highly endemic areas, MOI has been found to be lower in clinical episodes 
compared to asymptomatic carriage [8-11]. In prospective studies including mostly older 
children, MOI also seems to protect against subsequent malaria morbidity [12-15]. Such 
protective effects could be explained as result of cross-protection against super-infecting 
parasites (premunition). No such effect was observed in a study in infants in a highly endemic 
area in Tanzania, where the opposite was found: an increased risk of a febrile episode with 
increasing number of parasite clones [16]. Other studies confirmed MOI to be a risk factor for 
clinical malaria in infants or young children and in individuals from areas of low transmission 
intensity [17-21]. These opposing age-specific effects of MOI were delineated for areas of 
high malaria transmission where in children >3 years multiple concurrent infections have a 
protective effect, whereas in children <3 years MOI seems to be a risk factor by each 
additional new infection adding to the risk of developing a morbid episode [5,17,21]. 
 
Malaria is endemic in lowland areas of PNG and the malaria situation is characterized by the 
presence of all four Plasmodium species that affect humans. This makes it possible to study 
interactions among different Plasmodium species. Earlier studies found fewer mixed species 
infections than would be expected by chance, indicating that co-infecting parasite species 
interact [22]. A study in Thailand [23] showed a reduced risk of severe malaria in patients co-
infected with P. falciparum and P. vivax compared to patients infected with P. falciparum 
alone. Species interactions have also been proposed in a study from Vanuatu where P. 
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falciparum and P. vivax co-exist [24]. In a prospective study in PNG, P. malariae positivity 
was associated with protection against subsequent morbidity, though this effect was not 
specific for malaria morbidity. In the same study a P. vivax infection was found to protect 
specifically against a subsequent P. falciparum episode [25]. In contrast, an increased risk of 
severe malaria was reported for Papua New Guinean children under 5 infected with P. 
falciparum plus  P. vivax [26] and a further study in PNG also failed to find protective effects 
of heterologous infection at baseline against subsequent re-infection or P. falciparum illness 
[27].  
 
None of these studies so far has taken into consideration the effect of mixed-species infections 
on multiple-clone infections. This shortfall is addressed by the present investigation. In a 
longitudinal study of 269 Papua New Guinean children participating in regular follow-up 
visits over a period of 16 months, we investigated the genetic profile of parasites from 
symptomatic and asymptomatic infections. The aim of this study was to assess the impact of 
mixed species infections on P. falciparum clone multiplicity and to define parasitological risk 
factors for malaria morbidity in 1-4.5 year old children from PNG. 
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METHODS 
 
Field survey and patients 
This study was conducted in the vicinity of Ilahita health centre, in a rural area near Maprik, 
East Sepik Province, Papua New Guinea. A detailed description of the study is given 
elsewhere (Lin et al., in preparation). Briefly, 269 study participants were enrolled at an age 
of one to three years starting in March 2006. Regular follow-up visits were conducted in 8-
weekly intervals over a period of 16 months until July 2007. Except for the first and last 
round of sample collection, two consecutive blood samples were collected by finger prick at 
intervals of 24 hours for each study participant at each follow-up visit; i.e. each individual 
contributed up to seven 24 hour-sample pairs plus two rounds of simple bleeds. Active and 
passive case detection was performed in between the regular 8-weekly follow-up visits and a 
blood sample was collected from all participants with suspected malaria infection and a rapid 
diagnostic test (RDT) was performed. Antimalarial treatment with Coartem® (Novartis, 
Switzerland) was administered upon a positive RDT or if haemoglobin levels were <7.5 g/dl. 
Informed consent was sought from all parents or guardians prior to recruitment of each child. 
Scientific approval and ethical clearance for the study was obtained from the Medical 
Research and Advisory Committee (MRAC) of the Ministry of Health in PNG and from the 
Ethikkommission beider Basel in Switzerland.  
 
 
Laboratory procedures 
All finger prick blood samples were separated into plasma and cells. DNA was extracted from 
cell pellets using QIAamp® 96 DNA Blood Kit (Qiagen, Australia) according to the 
manufacturer’s instructions. All samples were genotyped for the polymorphic marker gene 
merozoite surface protein 2 (msp2) by use of capillary electrophoresis as previously described 
by Falk et al. [28] with some minor changes and adaptations of PCR conditions for highly 
purified DNA as described by Schoepflin et al. (manuscript in preparation).  
 
 
Data analysis 
All samples that were positive by msp2 PCR were classified as either an episode or 
asymptomatic infection. An episode was defined by a positive msp2 PCR plus fever (i.e. 
axillary temperature >=37.5°C) or a history of fever in the last two days and / or a parasite 
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density of >5000 parasites/µl. For the analysis of this work only one sample of each 24 hour 
bleed was taken into account. If both consecutive samples were classified as being 
asymptomatic or symptomatic, respectively, the sample collected on the first day was 
included in the analysis. If either sample was classified as clinical episode and the other one 
representing an asymptomatic infection, the episode sample was considered for data analysis. 
Infections were classified as mixed species infection if msp2 PCR was positive and light 
microscopy indicated the presence of at least one other Plasmodium species. A non-
parametric Wilcoxon-rank sum test was used to compare parasite densities between groups. 
Proportions were compared between groups using chi square test. Linear regression was 
applied to test for correlations between numerical variables. The incidence of episodes (λ) 
was calculated as
∑ t
n
, where n is the total number of episodes and t is the number of days 
each individual was under observation during the study.  
 
For analysing the persistence of an allele prior to the episode, those episodes were excluded 
that carried mixed species infections. The presence or absence of each allele was recorded for 
all samples collected prior to the episode. If an antimalarial treatment was given at an earlier 
time point, only samples collected after the last treatment were included.  
 
The dataset used for analysing risk factors for a P. falciparum episode contained all 
asymptomatic infections, irrespective of the infecting Plasmodium species and all morbid 
episodes that were uniquely positive for P. falciparum. Each blood sample from an episode 
was matched to the sample of the same child collected at the preceding follow-up visit. 
Sample pairs were excluded from this analysis if antimalarial treatment was given at the time 
of collection of the previous sample or if there was any antimalarial treatment in between 
these paired samples. Logistic regression analysis was used to estimate the effect of 
parasitological parameters of the precursor sample on the outcome of an infection. Models 
were compared using AIC (Akaike's Information Criterion) as measure of goodness of fit. 
Lower values of AIC indicate a better fit to the data. Statistical significance was tested using 
likelihood ratio test.  
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RESULTS 
 
Parasitological parameters in episodes and asymptomatic infections 
1334 of 3216 samples genotyped were positive by msp2 PCR. Of these 787 derived from 
malaria episodes and 547 from asymptomatic children. An episode was defined by a positive 
msp2 PCR plus fever (i.e. axillary temperature >=37.5°C) or a history of fever in the last two 
days and / or a parasite density of >5000 parasites/µl. Of all PCR positive blood samples, 844 
were infected by P. falciparum only and did not contain any other Plasmodium species 
according to the results of light microscopy. 533/844 derived from symptomatic individuals. 
We further detected 490 samples carrying a mixed infection with P. falciparum plus any other 
species, the majority of these (426 samples) being  P. falciparum / P. vivax mixed infections. 
The incidence of malaria episodes (λ) was estimated approximately 2.5 episodes per child per 
year. When considering episodes containing only P. falciparum and no other Plasmodium 
species, λ was approximately 1.7 P. falciparum episodes per child per year.  
 
We analyzed the representation of allelic families and parasite density in symptomatic and 
asymptomatic infections. A previous genotyping study had reported higher parasite densities 
in symptomatic episodes of FC27-type infections compared to 3D7-type infections [21]. We 
also observed an increased parasite density in episodes carrying a single Fc27-clone 
(63884.66 parasites / µl, CI [50021.6, 77747.7]) compared to 3D7-episodes (42978.9 parasites 
/ µl, CI [32953.6, 53004.2]) (Z=-1.9, p=0.056). No difference in parasite density was 
observed in Fc27- and 3D7-type asymptomatic infections (p=0.53). Previous studies reported 
an association between the infecting allelic family and morbidity [19,29]. In our dataset, we 
could not confirm Fc27-type genotypes to be associated with morbidity. The proportion of P. 
falciparum episodes carrying only Fc27-type alleles was similar in symptomatic and 
asymptomatic infections (χ2=0.02, p=0.89). The same was true, when only P. falciparum 
episodes were considered that contained > 5000 parasites / µl (χ2=0.05, p=0.82).  
 
P. falciparum episodes were further characterised by the persistence of all parasite clones 
prior to the episodes. For this analysis 470 samples from morbid episodes harbouring 699 P. 
falciparum clones were available. The majority of all episodes (91.8 %) contained msp2 
alleles that were not present in the samples collected prior to the episode (Figure 3). Very few 
genotypes (6%) persisted longer than 7 days. As our longitudinal study has scheduled 
sampling in 2-monthly intervals, the distance between an episode and the preceding follow up 
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sample of the same child ranged between 1 and 60 days. On average, the last follow-up 
sample was collected 30 days prior to the episode. Thus, alleles newly appearing in an 
episode were acquired within the preceding 30 days. The previous persistence of parasite 
clones in episodes was determined from all preceding samples of the corresponding child 
since the last antimalarial treatment. This retrospective analysis provides an estimate of the 
minimal persistence of a clone causing a morbid episode. The 2-monthly spacing of regular 
follow-up bleeds does not allow a more precise determination of the time point at which a 
new clone first appeared. 
 
The prevalence of infection significantly increased with increasing age (LR χ2=54.02, 
p<0.001) (Figure 1). The mean number of concurrent infections has been reported to be age 
dependent [5,6,11,18,30]. In contrast to these studies, mean MOI did not change when 
children grew older for both, asymptomatic and symptomatic infections in our study 
(asymptomatic infections: F= 3.31, p=0.07; episodes: F= 0.01, p=0.9) (Figure. 2). Unlike 
previous findings [8,9,11] mean MOI did not differ between P. falciparum episodes and 
asymptomatic infections in both age groups (< and ≥ 3 years) of our study participants (Table 
1). Furthermore, we investigated the effect of a concurrent heterologous species infection on 
MOI. We found a higher mean MOI in infections that also harboured other Plasmodium 
species compared to those carrying only P. falciparum clones. This was statistically 
significant for children older than 3 years (Table 1).  
 
 
Risk factors for P. falciparum episodes 
The number of episodes was significantly correlated to age (LR χ2=27.48, p<0.001). We 
observed an increase in the prevalence of P. falciparum disease with increasing age and peak 
prevalence of disease was reached in children between 3 and 3.5 years of age followed by a 
subsequent decline in older children (Figure 1). We investigated the effect of parasitological 
status of the preceding sample on incidence of clinical malaria. We found that the risk of P. 
falciparum episodes decreased with increasing MOI in the previous sample (Figure 4). 
Previous reports indicated that in children less than 3 years of age multiple infections seem to 
be associated with a higher prospective risk of clinical malaria [17,21], whereas in older 
children a higher MOI had a protective effect [12-14,21]. Therefore, we did separate logistic 
regression analysis for these two different age groups (Table 2). MOI at the previous visit had 
a significant protective effect against development of an episode in children aged 3 years or 
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older. This is in line with previous results from Africa [12-14,21]. No significant effect of 
MOI on a subsequent episode was found for younger children. We further tested, whether the 
presence of 3D7 or Fc27 type alleles could be defined as risk factors for a subsequent P. 
falciparum episode, but neither of them was found to have a significant effect on the outcome. 
For children < 3 years, the model with the best AIC value also included the presence of P. 
vivax in the preceding sample. A P. vivax was a risk factor for a subsequent P. falciparum 
episode in this age group. In older children the model with the best AIC included the presence 
of P. malariae in the precursor sample, which was found to have a protective effect against a 
P. falciparum episode (Table 2).  
 
Analysis of risk factors was also performed on episodes classified according to the presence 
of either msp2 allelic family. Different parameters of the precursor samples were tested as risk 
factors for a subsequent 3D7- or Fc27-type episode by logistic regression analysis (Table 3). 
No significant allele-specific effects of precursor infections were observed for the two age 
groups. A preceding P. vivax infection was found to increase the risk for subsequent Fc27-
type episodes in children under 3 years. This trend was significant, irrespective of whether the 
precursor sample contained P. vivax only or in combination with other Plasmodium species. 
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DISCUSSION 
 
Based on longitudinal sampling and genotyping of individual P. falciparum clones we aimed 
at identifying parasitological risk factors for a clinical malaria episode in children younger 
than 5 years in Papua New Guinea. The peak prevalence of P. falciparum disease was at 3 to 
3.5 years, which agrees with previous studies in PNG [2,3]. A slight decline in the number of 
episodes in children older than 3.5 years is indicative for the development of immunity after 
repeated infections. 
 
A previous study from a highly endemic area in Tanzania reported a lower mean MOI in 
symptomatic children between 1 and 5 years compared to asymptomatic children [8]. Similar 
results were reported from children living in a high transmission area in Senegal [9]. In 
contrast to these reports, we found mean MOI to be similar in episodes and asymptomatic 
infections in both, children younger and older than 3 years. This difference could be explained 
by the frequent treatment administered to children participating in our survey. In our tightly 
surveyed study group treatment was given to each child on average every 86 days. Since 
transmission intensity is much lower in PNG compared to the previously mentioned study 
sites [31], intervals between treatments were probably two short to allow for development of 
high multiplicity and thus we did not detect a difference in MOI between asymptomatic and 
symptomatic infections. As a consequence of our active case detection, the asymptomatic 
infections in this study do not reflect chronic asymptomatic carriage persisting in absence of 
treatment over extended periods of time but must be considered of quite recent origin.  
 
Few studies have investigated the dynamics of genotypes when the status of a child changed 
from asymptomatic infection to a clinical episode [9,32]. Our longitudinal survey permitted to 
investigate in a large sample set the presence of alleles before and at morbid episodes. 
However, our study does not provide samples collected daily or in short intervals. We 
therefore estimated the minimal persistence of each allele. The measure underestimates the 
true duration of the P. falciparum clone causing an episode. This fact did not compromise our 
estimates substantially because the great majority of alleles detected in episodes were not 
present in the sample prior to the episode, collected on average 30 days ahead of the episode. 
These findings support previous studies [9,32], where children were followed up in closely 
spaced intervals and genotypes in episodes had also newly appeared. However, treatments 
were given in our study very frequently, on average every 86 days. Such frequent treatment 
CHAPTER 6 
 117 
resulted in a high turnover rate of parasite clones. Therefore, very few long term persisting 
asymptomatic clones were observed in the entire study and we cannot conclude from our data 
that persisting infections did not contribute to morbidity as well. 
 
It has been reported previously that higher MOI protects older children or semi-immune 
adults against subsequent morbidity [12-15,21]. The high number of antimalarial treatments 
in our study most likely has affected the development of acquired immunity in study 
participants, since frequent treatment does not allow accumulation of multiple parasite clones 
within a host. This might result in a lack of protective effect of persisting asymptomatic 
infections on subsequent malaria morbidity. However, despite this impediment through 
frequent treatment, we found in a prospective analysis of parasitological risk factors for P. 
falciparum episodes that high MOI protected older children (> 3 years) against a subsequent 
clinical attack. These results reinforce previous findings [12-15,21] and are consistent with 
the concept of premunition [5], i.e. ongoing asymptomatic infections offer cross-protection 
against invading clones. In children < 3 years no significant effect of MOI on subsequent 
morbidity was observed in our study. This contrasts to previous studies that found a positive 
correlation of MOI and subsequent episode in this younger age group [17,21] which is 
thought to be an indication for the lack of previous exposure and therefore development of 
immunity.  
 
In previous reports Fc27-type infections were associated with symptomatic infections. This 
was reflected in higher Fc27-parasite densities [21,33] or a higher proportion of Fc27-type 
alleles in episodes [19,29]. In agreement with earlier results, we observed an increased 
parasite density in episodes caused by a single Fc27-type clone compared to episodes caused 
by a 3D7-clone. But in our study Fc27-type alleles were equally prominent in both, samples 
collected during morbid episodes and in asymptomatic samples. This is in agreement with 
results from a previous study conducted in the same area in PNG, where also no association 
between the presence of Fc27 alleles and clinical malaria had been found [11]. Our results 
indicate that both allelic families are equally contributing to morbidity, but the fact that Fc27-
type infections take higher parasite densities are supporting previous suggestions that Fc27-
type infections might be more successful in evading the host’s immune response [21].  
 
Our prospective analysis did not reveal any significant allele-specific effects on a subsequent 
P. falciparum episode per se (Table 2). In the separate analysis of risk factors for Fc27- or 
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3D7-type episodes, we did not find any allele-specific effects on the prospective risk of 
developing a 3D7- or Fc27-episode (Table 3). This finding suggests that within the short time 
interval including both paired samples, no allele-specific protection was elicited through the 
most recent and ongoing genotype. An asymptomatic and a symptomatic clone could 
establish equally well in new hosts and seem not to be prevented by a previous response 
against family-specific epitopes. This contrasts the assumption that protective responses to the 
family-specific domains of MSP2 are very short-lived and dependent on the most recent 
infection. Our study suggests that strain-specific immunity against MSP2 antigens is not 
raised within such a short period of 38 days on average and that immunity does not primarily 
reflect the response against the most recent infecting clone. Our data support previous 
findings that in an early stage of the developing immune response in younger children, 
defence mechanisms against parasitism are rather unspecific and act via high fever and 
cytokine effects [34], while the specific immune responses and possibly cross-protecting 
effects only develop in older children. 
 
A P. vivax infection in children <3 years appeared to be a risk factor for a subsequent P. 
falciparum episode, with the risk for an Fc27-type episode being highly significantly 
increased. It is likely that the preceding P. vivax infection reflects higher exposure, as P. vivax 
and P. falciparum are transmitted by the same vector. If this is true, a previous P. falciparum 
infection would be expected to have a similar effect on a subsequent episode. Indeed, a 
similar trend was observed for a preceding P. falciparum infection, though this trend was not 
statistically significant (data not shown). We assume that the risk through a preceding P. vivax 
was only observed for Fc27-type episodes because these occur in higher densities.  
 
A further intention of this work was to identify effects of co-infecting Plasmodium species. A 
comprehensive analysis of cross-species interactions will be presented elsewhere (Mueller et 
al., in preparation). An important finding was a lower proportion of episodes in mixed species 
infections and lower P. falciparum densities in sample concurrently infected with other 
Plasmodium species. This indicated interdependence among co-infecting Plasmodium 
species. We examined whether species interaction affected P. falciparum MOI. We observed 
in older children that mixed species infections harboured significantly more parasite clones 
than single species P. falciparum infections (Table 1). This is in line with the observed 
reduced densities in mixed species infections, as lower densities might have reduced the need 
for treatment and thus could have allowed accumulation of multiple clones.  
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In summary, our data highlights interdependence among co-infecting Plasmodium species and 
among clones of multi-clone P. falciparum infections. Moreover, in children >3 years 
multiple infections seem to confer protection against subsequent P. falciparum episodes. Such 
findings have implications for the development and introduction of malaria control 
interventions, e.g. for the treatment policy of asymptomatic infections in older children. 
Similarly, in view of protection through co-infecting species, interventions targeting only one 
species might have important adverse effects on the outcome of infections with other species. 
Future studies investigating in parallel the multiplicity of P. vivax infections might provide 
additional insights into interactions between clones of P. falciparum and clones of P. vivax. 
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Table 1: Mean multiplicity of infection by morbidity status and co-infection with other 
Plasmodium species.  
 age group < 3 years  age group ≥ 3 years 
 
asymptomatic infections 
[95 % CI] 
symptomatic infections                                 
[95 % CI]  
asymptomatic infections 
[95 % CI] 
symptomatic infections                                 
[95 % CI] 
 n=369 n=551 
 
n=178 n=236 
Mean MOI 1.45 1.51  1.52 1.57 
 [1.36, 1.54] [1.43, 1.58]  [1.4, 1.64] [1.45, 1.68] 
 p=0.1  p=0.7 
      
      
 age group < 3 years  age group ≥ 3 years 
 
mixed species infections 
[95 % CI] 
P. falciparum infections  
[95 % CI]  
mixed species infections 
[95 % CI] 
P. falciparum infections  
[95 % CI] 
 n=347 n=573 
 
n=143 n=271 
Mean MOI 1.55 1.45 
 
1.69 1.47 
 
[1.45, 1.65] [1.37, 1.52] 
 
[1.52, 1.85] [1.38, 1.57] 
 p<0.07  p<0.05 
 
 
Table 2: Logistic regression analysis of factors affecting the morbidity outcome  
CHILDREN <3 years (n=294)    
Risk factors OR 
Likelihood  
ratio χ2 p-value 
P. vivax in previous sample 1.89 6.99 <0.01 
MOI in previous sample 0.59 1.71 0.19 
Fc27 type allele in previous sample 1.63 0.77 0.38 
3D7 type allele in previous sample 1.32 0.23 0.63 
    
    
CHILDREN >=3 years (n=152)    
Risk factors OR 
Likelihood  
ratio χ2 p-value 
P. malariae in previous sample 0.11 5.43 <0.05 
MOI in previous sample 0.7 3.96 <0.05 
3D7 type allele in previous sample 1.39 0.34 0.56 
Fc27 type allele in previous sample 0.91 0.03 0.86 
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Table 3: Logistic regression analysis of factors affecting the outcome of subsequent Fc27- or 
3D7-type infections 
 
Age group < 3 years 
n=193 (128 asymptomatic 
infections; 65 Fc27 episodes) 
Age group >= 3 years 
n=89 (54 asymptomatic 
infections; 35 Fc27 episodes) 
Risk factors for an Fc27-type episode OR 
Likelihood 
ratio χ2 p-value OR 
Likelihood 
ratio χ2 p-value 
MOI in previous sample 0.63 0.46 0.5 0.94 0.01 0.93 
3D7 type allele in previous sample 0.43 0.69 0.41 0.13 2.51 0.11 
Fc27 type allele in previous sample 1.97 0.61 0.43 0.69 0.12 0.73 
P. vivax in previous sample* 2.79 10.18 <0.01 0.96 0.01 0.94 
       
       
 
Age group < 3 years 
n=194 (128 asymptomatic 
infections; 66 3D7 episodes) 
Age group >= 3 years 
n=95 (54 asymptomatic 
infections; 41 3D7 episodes) 
Risk factors for a 3D7-type episode OR 
Likelihood 
ratio χ2 p-value OR 
Likelihood 
ratio χ2 p-value 
MOI in previous sample 0.5 1.66 0.2 0.89 0.03 0.86 
Fc27 type allele in previous sample 1.23 0.07 0.8 0.16 2.65 0.1 
3D7 type allele in previous sample 2.75 1.89 0.17 0.62 0.23 0.63 
P. vivax in previous sample 1.3 0.71 0.4 0.69 0.67 0.41 
 
* presence of P. vivax alone or as mixed species infection with any Plasmodium species 
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Figure 1: Prevalence of P. falciparum infection (solid line) and of P. falciparum disease* 
(dashed line) in cross sectional surveys.  
*Disease was defined as positive msp2 PCR plus fever (i.e. axillary temperature >=37.5°C) or 
a history of fever in the last two days and / or a parasite density of >5000 parasites/µl. 
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Figure 2: Mean multiplicity of infection (including only samples with MOI>0) from children 
aged 1 – 4.5 years. ▲ samples from symptomatic children carrying P. falciparum only. □ 
samples from asymptomatic children. Pf= P. falciparum  
age (years) 
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Fig. 3: Persistence of alleles prior to an episode caused by P. falciparum  
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Figure 4: Risk of P. falciparum episodes at time t in relation to multiplicity of infection 
(MOI) in the preceding sample (time t-1). 
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group 1: allele first seen at episode
group 2: allele seen up to 7 days prior to episode
group 3: allele seen up to 14 days prior to episode
group 4: allele seen > 14 days prior to episode
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CHAPTER 7: General discussion  
 
Under the auspices of the Institute of Medical Research in Papua New Guinea, a longitudinal 
field survey was conducted in a cohort of 269 children between 1-4.5 years of age from a 
malaria endemic area. The main goal of the PNG field study was to assess the existence of 
cross-species protection against malarial morbidity, with a particular focus on whether 
asymptomatic infections protect against subsequent morbidity due to heterologous infections. 
The objectives of this PhD thesis were in parts nested within the field project’s focus on 
species interactions by contributing genotyping data for P. falciparum. This permitted a view 
on species interactions on the level of individual parasite clones. Genotypes of parasites were 
compared between phases of asymptomatic carriage and morbid episodes in order to define 
parasitological risk factors for malaria morbidity and to determine the impact of co-infection 
with a heterologous species on the multiplicity of infection. 
 
Other objectives of this thesis were developed as ancillary studies to the main field project 
making further use of the longitudinal samples collected during the 16 months follow-up 
period. A major focus was on estimating the loss of fitness caused by mutations associated 
with drug resistance. The aim was to make use of classical malariological parameters in 
combination with molecular parameters describing infection dynamics of P. falciparum to 
describe the survival and model the transmission success of resistant versus sensitive parasite 
clones. This exploratory project was carried out in 2 steps, involving samples from two 
different field studies: one earlier treatment to reinfection study [1] and the 16 months 
longitudinal study. 
 
 
Fitness costs of drug resistance 
Mutations associated with antimalarial drug resistance are thought to be disadvantageous for 
parasites once drug pressure is abolished. Experimental evidence does not only come from in 
vitro experiments [2] or mouse models [3,4], but also from field studies in the human host [5-
7]. Because fitness in terms of transmission success of Plasmodium parasites cannot be 
determined experimentally in a simple and straight forward way, a surrogate marker for 
fitness would be helpful to quantify the loss of fitness associated with drug resistance 
mutations. We hypothesised that the survival of parasite clones within human hosts can be 
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used as surrogate for transmission probability. If this assumption was true, one would expect 
to find differences in drug resistance mutations in persisting versus short term infections. If 
drug resistance mutations incur a fitness cost by impairing the parasites’ survival, long term, 
chronic infections should harbour less SNPs compared to rapidly cleared infections. This 
difference could be observed only in absence of drug pressure. Our approach considers all 
known SNPs from several genes associated with drug resistance summarized as drug 
resistance haplotype.  
 
Determination of the haplotype of a clonal infection is straight forward only in single clone 
infections. In areas of high MOI, identification of all haplotypes of multiple co-infecting 
clones is impossible. In PNG, mean MOI for P. falciparum is low and most individuals 
harbour single clone infections ([8,9], and own data) making it possible to clearly assign drug 
resistance haplotypes. Thus, low MOI in PNG offers optimal study conditions to investigate 
effects of haplotypes of drug resistance mutations on parasite fitness.  
 
In a first attempt to measure fitness costs incurred by drug resistance we tested whether 
reduced parasite fitness could be measured as effect on parasite survival. We compared the 
drug resistance haplotypes of single clone infections between new infections acquired after 
radical cure and chronic infections in adults from an endemic area in PNG. A reduced 
frequency of a 7-fold mutated haplotype and increased frequency of a 5-fold mutated 
haplotype in long term persistent infections indicated an impaired fitness of highly mutated 
parasites to develop into chronic infections. These results suggested that it’s a suitable 
approach to use the duration of an infection as marker for parasite fitness. However, the 
disadvantage of this pilot study was that samples from adults derived from a cross-sectional 
study and consequently, the duration of persistence of the detected parasite clones in these 
samples was not known. Instead it was assumed that adults carry long term infections, based 
on previous results from an endemic area in Africa [10].  
 
Better estimates of the reduction in parasite survival due to the presence of mutations would 
be achieved by correlating the actual persistence determined by longitudinal tracking of 
individual clones to the drug resistance haplotype of each clone. Such an analysis requires a 
sufficient number of infections that have not been cleared by antimalarial treatment. We 
intended to retrieve these samples from untreated periods of several months from the 
longitudinal study in children from PNG. However, a great proportion of all newly acquired 
CHAPTER 7: GENERAL DISCUSSION 
 129 
infections caused a clinical episode which had to be treated with antimalarials. This prevented 
the establishment of long-term persisting infections and led to a high turn-over of parasites in 
our study children. Only very few long term infections were observed in our cohort of young 
children. Therefore, the samples collected in our longitudinal field study could be used to 
estimate the clone acquisition rate, but were not suitable for estimating natural clearance rates 
and clone persistence.  
 
There are several reasons for the high number of treatments administered to the study 
participants. On one hand, the age group enrolled in our study accounts for precisely the 
fraction of the population with the greatest burden of disease. On the other hand it is possible 
that the study design including active and passive case detection might have resulted in an 
increased frequency of treatment. This might have led to an impaired development of 
immunity, and as a consequence each newly acquired infection caused another symptomatic 
episode that had to be treated. Thus, the establishment of asymptomatic long-term infections 
was affected. Furthermore, according to the standard treatment in PNG all Plasmodium 
infections that were associated with anaemia (Hb<7.5g/dl) had to be treated with 
antimalarials, irrespective of the presence of malaria symptoms. This further increased the 
amount of Coartem® dispensed during the course of our study.  
 
Deprived of the possibility to estimate duration of infections, we were not able to determine 
the association between molecular markers of drug resistance and the persistence of parasite 
clones. This part of the initial work plan had to be postponed until a new set of samples from 
older and untreated individuals becomes available. We expect that in an age group older than 
the one studied here, infections less frequently cause morbid episodes requiring treatment. 
While adults seem to be optimal, these age groups are not easily available for longitudinal 
surveillance because of occupational constraints or migration. Thus, the group of oldest 
school children seems to be the most suitable study group for obtaining infections of 
potentially long duration. 
 
Outlook  
After completion of this PhD thesis, it is foreseen to subject the limited number of persisting 
single clone infections detected in our field study to characterization for drug resistance SNPs 
and to compare results to haplotypes of the abundant new infections. This approach is similar 
to the one of our pilot study except that our first approach [11] only assumed a persisting 
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infection, while now we can delineate the duration of haplotyped clones. We expect to collect 
further data supporting our previous results of differential distribution of drug resistance 
haplotypes in new versus persisting infections. A more pronounced difference in the 
haplotype frequency between new and persistent infections may be detected, because the data 
from our longitudinal study are less prone to assumption errors. However, as the available 
samples from persisting infections will not exceed 50 parasite clones, and because durations 
are limited to >2 months, further mathematical modelling might not be possible due to scarce 
data.  
 
Relevance of this project 
Detailed investigations of fitness costs of drug resistance might have important implications 
for the guidance of treatment policies and for the ongoing efforts to best manage the 
implementation of new antimalarial drugs in a country. If fitness costs of drug resistance are 
high enough to lead to a resurgence of wild type alleles once the specific drug usage is 
discontinued, this might results in the possibility of re-using this drug at a later time point. 
This is a particular advantage for the use of CQ, as this drug has been a widely available, 
effective, safe and affordable antimalarial for a long time. However, it should be decided with 
great care about the re-introduction of drugs, and in any case this should be done in a 
combination with other effective partner drugs. A rotative usage of drugs over intervals of 
years in well matched combination therapies has recently been proposed [12]. Though this 
might be a conceivable solution to control the spread of drug resistance, it might practically 
be very difficult to achieve in routine clinical practice as it seems to be important to achieve a 
complete replacement of drugs. This emerged from of a recent first approach to estimate the 
fitness costs of drug resistance based on the reduction of the mutant pfcrt76 allele in Kenya 
and Malawi [5,6] after the cessation of CQ as first line treatment. A much lower estimate of 
fitness costs was estimated for Kenya compared to Malawi (5% vs. 12%). Ineffective 
replacement of CQ and sustained use of AQ, which is a close analogue of CQ and known to 
select for pfcrtK76T were proposed to have contributed to the lower fitness costs in Kenya. 
These findings further indicate that the type of drug that is used to replace the ineffective 
treatment regimen might play a crucial role whether and to what extent a reduction of the 
resistant parasite population can be achieved. Since Coartem® was found to select for the wild 
type pfmdr1 N86 and pfcrt K76 alleles [13-18] which are associated with CQ sensitivity this 
seems to be an ideal drug for replacement of CQ.  
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Infection dynamics of P. falciparum  
Advances in the development of molecular genotyping techniques have greatly increased our 
knowledge of the population structure and genetic profile of Plasmodium infections and has 
given insights into the dynamics and complexity of infections. Optimal discrimination of 
parasites within a host can be achieved by choosing a marker gene that is highly polymorphic 
and shows a homogeneous distribution of allele frequencies. The quality of genotyping can 
further be improved by the technique applied to determine individual clones. In the course of 
this thesis we have developed an improved protocol for genotyping the polymorphic marker 
gene merozoite surface protein 1 (msp1) based on capillary electrophoresis. It has previously 
been shown for msp2 that capillary electrophoresis has a greater discrimination power than 
previously applied techniques [10]. We have compared the allele frequency distribution of 
msp1 and msp2 for two countries of different endemicity (PNG vs. Tanzania (TZ)) and 
showed that in both countries msp2 was most polymorphic. Our results confirmed previous 
reports of an increased diversity of msp2 with increasing endemicity [19-22]. In TZ the 
probability of two parasites sharing the same msp2 allele was low and indicated that msp2 
could qualify to be used as a single marker for genotyping. However, the high MOI observed 
in Tanzanian samples likely has a negative impact on discrimination power because each 
additional co-infecting clone increases the chance to become superinfected with a clone 
already present. To quantify this effect of MOI we made an attempt to estimate the probability 
of observing the true number of alleles present in a host. This probability was found to rapidly 
decrease with increasing MOI. The fact that high MOI reduced discrimination power 
highlights the importance of genotyping more than one marker gene. Our results are of 
particular importance for genotyping samples from drug efficacy trials where recrudescent 
and new infections have to be reliably distinguished and the probability of newly infecting 
parasites having the same allele as an initial infection should be minimized. 
 
Consecutive blood sampling from the same individual has previously shown that parasite 
populations undergo rapid fluctuations [23,24] and that a single sample underestimates the 
true MOI. In order to estimate the detectability of parasite clones in our study and to assess 
the benefit of drawing repeated blood samples 24 hours apart, we genotyped two consecutive 
blood samples from each participant collected at all regular follow-up bleeds. In contrast to 
previous estimates [10,25], which had included participants of all age groups, we estimated an 
overall very high detectability in our group of young children. In endemic areas parasite 
densities are usually higher in young children compared to adolescent or adults [26-29]. This 
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suggests that the high detectability determined by us is likely a result of high parasite 
densities in our age group.  
 
We have investigated the effect of collecting 2 samples 24 hours apart on the outcome of 
basic epidemiological parameters. As expected, we obtained more accurate estimates of the 
parasite population within a host which was reflected in a slight increase of the mean MOI 
when genotyping results from both days were combined. We further showed that in our study 
cohort the risk of acquiring new infections increased as children grew older and that 
collecting 24 hour bleeds resulted in a small increase of the measured FOI. Since the observed 
age-trend remained similar and the increase in MOI was only marginal, it does in our opinion 
neither justify the immense additional costs and logistical efforts associated with this study 
design nor the additional discomfort caused to the study participants. Therefore, for this age 
group we consider it unnecessary to collect repeated samples in short intervals, i.e. after 24 
hours, for studies investigating basic epidemiological parameters. It has been shown that in 
endemic areas, detectability greatly depends on the age of the host with a drastic decrease in 
detectability in adults [25]. Therefore, the above conclusion on repeated sampling might not 
be appropriate for semi-immune individuals in endemic areas who better control parasites and 
consequently carry low-parasite density infections that fluctuate around the detection limit of 
PCR techniques. 
 
Imperfect detectability likely has important implications for the accuracy of results from drug 
efficacy trials. Suboptimal clone detection during molecular genotyping of baseline and 
follow-up samples leads to an underestimation of the number of recrudescent infections. A 
recent drug efficacy trial conducted in Tanzania indeed reported a lower efficacy of the tested 
drug therapies when an enhanced protocol was applied which included consecutive blood 
sampling following enrolment and follow-up visits compared to the standard protocol 
generally applied [30]. Despite the reported benefit of repeated sampling reported from this 
study, WHO and Medicines for Malaria Venture (MMV) currently do not recommend 
conducting 24 hour sample collection after baseline and follow-up samples. Reasons for this 
include very fast acting new drugs leading to negative samples on day 2, additional costs, 
involvement of complex statistical analysis, lack of convincing evidence in favour of 24 hour 
repeated sampling, and the fact that patients would have been given rescue treatment on the 
follow-up visit in case of presence of parasites, irrespective of whether these are recrudescent 
or new infections [31]. Our finding of high detectability of parasite clones in our study 
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children supports these current recommendations, however for reasons stated above, this 
might not apply for drug trials conducted in older age groups. 
 
 
Coartem® treatment failures 
During the analysis of msp2 genotyping in our longitudinal samples, a high number of 
Coartem® treatment failures in treated children became evident. To confirm these treatment 
failures, we have genotyped a second marker, msp1. This genotyping system is also based on 
capillary electrophoresis and has high discrimination power. Genotyping of a third marker 
(microsatellite TA81) was performed by our collaborators from Case Western Reserve 
University (USA). We have shown in chapter 3 that genotyping of msp1 and msp2 resulted in 
a very low probability of observing a new infection with the same genotype than the one 
present in the treatment sample. Genotyping 3 molecular markers to distinguish recrudescent 
from new infections therefore provided a very high discriminatory power and confident 
identification of treatment failures.  
 
The high rate of parasitological and clinical treatment failures observed in our study differs 
remarkable from the report of a recent drug efficacy trial in PNG where Coartem® was found 
to be highly effective against P. falciparum [32]. Our results indicate poor adherence to the 
complex dosing regimen in combination with insufficient fat supplementation as potential 
explanation for the observed difference. Drug trials are likely to represent artificial conditions 
where compliance to drug regimens and fat supplementation are optimal. Our study better 
reflects the situation in routine practice, because treatments were mostly administered 
unsupervised and we did not provide any fat supplementation. Therefore, our results highlight 
a potential problem of Coartem® treatment in routine clinical practice and emphasize that the 
forthcoming introduction of Coartem® as first line treatment in PNG should be paralleled with 
provision of training and education of health workers in order to guarantee optimal 
compliance to the recommended treatment guidelines. It is essential to make great efforts to 
convince patients to complete the full regimen even after relief of symptoms. 
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Risk factors for clinical episodes 
The high frequency of clinical episodes in participants of our longitudinal field survey made it 
possible to assess parasitological risk factors for malaria morbidity in children under 5 years 
from PNG. Our prospective analysis indicated that interactions between different parasite 
clones do occur. In children >3 years, multiple clone infections were found to protect against 
a subsequent P. falciparum episode which was consistent with previous findings [33-36]. The 
occurrence of clone-interactions was further supported by our findings from estimating FOI. 
Using molecular typing techniques to distinguish individual parasite clones allowed us to 
estimate FOI in absence of antimalarial treatment. Comparison of estimates between absence 
and presence of treatment showed a lower FOI in absence of treatment. One explanation for 
this observed difference might be that asymptomatic infections cross-protect against newly 
invading parasites which might have resulted in a lower number of new clones acquired per 
survey interval. Substantial competitive interactions were also found in artificial infections in 
mice [37], where the outcome of competition was determined by several factors. The extent to 
which parasite clones suffered from competition was affected by the genotype of the infecting 
parasite, by the order in which parasites were inoculated, and by the duration of prior 
residency. All clones suffered from competition when they were simultaneously inoculated or 
after their competitor. Moreover, the longer the time between two inoculations, the greater 
was the competitive suppression of the first over the second clone. These results support our 
and previous ([29] and references therein) findings of asymptomatic infections protecting 
against superinfections. If asymptomatic multi-clonal infections offer cross-protection against 
superinfections, interventions targeting asymptomatic infections might have significant 
adverse effects on malaria morbidity, because treatment of asymptomatic infections might 
lead to clearance of the protective effect of already persisting infections.  
 
The presence of all four species infecting humans in PNG provides suitable conditions to 
study interspecific interactions between different Plasmodium species. If hosts harbour 
several related parasite species, these species are likely to interact by competing for resources, 
e.g. host cells. Such interactions could be antagonistic or asymmetrical, i.e. one species could 
have a negative effect on density or reproduction of the other. In contrast, sharing a host could 
also provide benefits for one of the species: the presence of one species could interfere with 
host defense mechanisms and could thus promote the multiplication rates of the other species. 
To elucidate this aspect of parasite ecology might have implications for antimalarial 
intervention strategies.  
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A number of previous studies indicated that interactions between species exist in natural 
populations, though results about cross-species protection have been inconsistent [1,38-40]. A 
comprehensive analysis of species interactions in our longitudinal study will be published 
elsewhere. In the course of this thesis, interactions were analysed with respect to multi-clonal 
P. falciparum infections. We observed a significantly higher MOI in samples that were 
concurrently infected with other Plasmodium species, supporting evidence for interactions 
among co-infecting species. This is in line with lower P. falciparum densities in infections 
simultaneously harbouring other Plasmodium species. Lower P. falciparum densities might 
have led to the decreased proportion of episodes observed in mixed species infections and 
consequently to fewer treatments which in turn might have allowed accumulation of multiple 
parasite clones. These findings are consistent with the idea that cross-species protection 
mainly acts via species transcending density regulation. In a study conducted in PNG, 
comprising sampling in short-term intervals over 61 days, Bruce and co-workers (reviewed in 
[41]) found that the total parasite density of all Plasmodium species fluctuated around a 
threshold and that peaks of infection with different species did not coincide. If more than one 
Plasmodium species occupy the same host, these must divide the available resources and will 
be affected by cross-reactive immune responses. Increasing densities of one species can have 
a negative effect on another by stimulating a host response that acts against both species. This 
might lead to lower parasite densities and, as morbidity is associated with high densities, to 
fewer episodes.  
 
Our results bear relevance for antimalarial intervention programmes. Should heterologous 
species interact within a host, interventions targeting only one species, such as vaccines, could 
potentially increase the burden of morbidity attributable to the other species.  
 
Outlook 
Important insights into species and clone interactions could be gained by genotyping P. vivax 
and P. falciparum co-infecting the same individual or by genotyping both species in samples 
collected longitudinally. A capillary electrophoresis based genotyping technique to 
distinguish individual P. vivax clones was recently developed at STI [42]. Using this 
technique, all P. vivax samples collected in our study cohort will be genotyped for the two 
most polymorphic markers. Complementing our data with genotypes of P. vivax will permit 
to study in great detail interactions between multi-clone infections of both Plasmodium 
species and their prospective effects on morbidity.  
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